

1 **A comprehensive overview of the role of intermolecular interactions in**
2 **amorphous solid dispersions.**

3 Lennert Cools^{a,b} and Guy Van den Mooter^{a*}

4 ^a *Drug Delivery and Disposition, KU Leuven, Department of Pharmaceutical and Pharmacological*
5 *Sciences, Campus Gasthuisberg ON2, Herestraat 49 b921, 3000 Leuven, Belgium*

6 ^b *Applied and Analytical Chemistry, NMR group, Institute for Materials Research (imo-imomec),*
7 *UHasselt, 3590 Diepenbeek, Belgium*

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

** Corresponding author:*

Guy Van den Mooter; Drug Delivery and Disposition, KU Leuven, Department of Pharmaceutical and
Pharmacological Sciences, Campus Gasthuisberg ON2, Herestraat 49 b921, 3000 Leuven, Belgium
Guy.vandenmooter@kuleuven.be; Tel.: +32 16 330304

35 **Graphical abstract**

36

37 **Abstract**

38 Many recent studies have indicated that drug-polymer intermolecular interactions are an important
39 aspect of amorphous solid dispersions (ASDs) and determine many of the properties of this type of
40 formulations. In this review, a comprehensive overview is given of the latest insights with respect to
41 intermolecular interactions in ASDs. The thermodynamic properties and theoretical considerations of
42 the interactions are discussed, followed by a detailed and critical overview of the various solid-state
43 analysis techniques used to probe interactions at the disposal of the formulation scientist. As the
44 physical stability and the pharmaceutical performance of the ASD are its most crucial properties, the
45 most recent understanding of the influence of drug-polymer interactions on these aspects is addressed
46 as well. It is clear that intermolecular interactions may provide many advantages for ASDs but need to
47 be weighed against the possible disadvantages. Further investigation into the interplay and trade-off
48 between physical stability and dissolution properties is necessary in order to be able to take full
49 advantage of the possible benefits of the interactions.

50

51

52 **Keywords:** *Amorphous solid dispersions – Intermolecular interactions – Stability – Drug release – Solid-*
53 *state analysis*

54

55 **Abbreviations**

AAPS	Amorphous-amorphous phase separation
API	Active Pharmaceutical Ingredient
ASD	Amorphous Solid Dispersion
BCS	Biopharmaceutics Classification System
CP/MAS	Cross polarization / Magic angle spinning
DFT	Density functional theory
DVS	Dynamic vapor sorption
FT-IR	Fourier transform infrared spectroscopy
HPMCAS	Hydroxypropyl methylcellulose acetate succinate
HPMCP	Hydroxypropyl methylcellulose phthalate
LLPS	Liquid-Liquid phase separation
LoC	Limit of congruency
mDSC	Modulated differential scanning calorimetry
PAA	Poly(acrylic acid)
PC-SAFT	Perturbed-chain statistical associating fluid theory
PDF	Pair distribution function
PEO	Poly (ethylene oxide)
PEtOx	Poly(Ethyl Oxazoline)
PVP	Poly(vinylpyrrolidone)
PVPVA	Poly(vinylpyrrolidone-co-vinylacetate)
ssNMR	Solid-state nuclear magnetic resonance
T_g	Glass transition temperature
XPS	X-ray photoelectron spectroscopy
XR(P)D	X-ray (powder) diffraction

56

57

58

59 **1. Introduction**

60 In recent years, the formulation of poorly water-soluble drugs as amorphous solid dispersions (ASDs)
61 has gained popularity as a means to enhance their solubility and bioavailability (Bhujbal et al., 2021a).
62 The growing need for such enabling strategies is driven by the fact that an estimated 50-90% of new
63 chemical entities are classified as poorly water-soluble according to the Biopharmaceutics
64 Classification System (BCS)(Benet, 2013; Ricarte et al., 2019). When a drug is formulated as an ASD, it
65 is molecularly dispersed within an inert carrier matrix, which disrupts the crystal lattice of the
66 compound and lowers the energy required for the drug molecules to dissolve. This results in higher
67 apparent solubility and faster dissolution compared to the pure crystalline material (Vaka et al., 2014).

68 Pure amorphous drugs possess higher free energy compared to their crystalline counterparts, making
69 them thermodynamically unstable (Van den Mooter, 2012), necessitating a carrier to stabilize the drug.
70 The inert carrier is most often of polymeric nature and stabilizes the drug in a variety of ways, reducing
71 the tendency for nucleation and crystal growth. The mobility of drug molecules is restricted in the
72 polymer matrix due to steric hindrance from the polymer chains and the generally higher glass
73 transition temperature (T_g) of the polymer, which increases the T_g of the system. Additionally,
74 dispersing the drug in the polymer matrix reduces the free energy of the drug (Baghel et al., 2016a).
75 Drug-polymer interactions can further stabilize the drug within the matrix, providing an additional
76 energy barrier that must be overcome for drug molecules to aggregate and crystallize (Janssens and
77 Van den Mooter, 2009). These interactions can include hydrogen bonding, halogen bonding, dipole-
78 dipole interactions, and ionic interactions, with their strength depending on the nature of the
79 interaction and the functional groups involved(Huang et al., 2008; Mesallati et al., 2017; Mistry et al.,
80 2015; Xiang and Anderson, 2019).

81 Research over the years has highlighted that intermolecular interactions influence every aspect of
82 ASDs, from solubility in the polymer matrix to physical stability, maximum drug loading, and drug
83 release. However, a comprehensive overview of how these interactions affect each aspect is still
84 lacking. This review aims to provide a thorough summary of the theory behind intermolecular
85 interactions in ASDs, the various methods to probe them, and their influence on maximum drug
86 loading, physical stability, and drug release.

87
88
89
90

91

92 **2. Background and theoretical considerations**

93 **2.1. Thermodynamics of interactions**

94 Intermolecular interactions can generally be subdivided in ionic interactions and interactions between
95 permanent or induced dipoles. The latter include van der Waals interactions (London, Keesom and
96 Debye) and hydrogen bonding, which are all attractive interactions, unless the distance between the
97 molecules becomes too small and the electron clouds of the atoms overlap, which causes repulsive
98 forces. Generally, for poorly soluble drugs and ASDs, neutral interactions are most important and
99 govern the properties of these systems. However, it has been reported in several instances that ionic
100 interactions between drug and polymer can also be present (Li et al., 2022; Mesallati et al., 2017). The
101 first part of this review will, however, focus on the neutral interactions as these are most important
102 for ASDs and will facilitate the explanation of the theoretical concepts.

103

104 **Figure 1**

105

106 These interactions can be described by plotting the potential energy as a function of the distance
107 between two molecules. When molecules are at a very short distance of each other, they will repel
108 each other and when subsequently brought further apart, the molecules will be attracted to each
109 other. The potential repulsive energy can be described by a/r^m , whereas the attractive potential energy
110 between the two molecules can be characterized by $-b/r^n$ (a and b are the repulsive and attractive
111 coefficients respectively, and m and n are selected positive integers). The sum of the attractive and
112 repulsive energies can be described as the total interaction energy E_{int} . The Lennard-Jones (L-J) model
113 is one of the more simplistic, yet popular models to describe the attractive and repulsive behavior of
114 two molecules (Wang et al., 2020). A typical representation of the behavior according to the L-J model
115 can be found in *Figure 1*, where the total interaction energy can be described by the following
116 equation:

$$117 \quad V_{LJ}(r) = 4\varepsilon \left(\left[\frac{\sigma}{r} \right]^{12} - \left[\frac{\sigma}{r} \right]^6 \right) \quad (1)$$

118 In this equation, r is the distance between two molecules, σ is the distance at which the potential
119 energy V is equal to zero and ε is the depth of the potential well. The minimum of the plot, where V_{LJ}
120 $= -\varepsilon$ and the distance between the molecules is equal to $2^{1/6}\sigma$, is the point where the greatest attractive
121 energy occurs. This distance is also denoted as r_{min} . The interaction force between the two molecules
122 can be described by the following equation:

123
$$F_{int} = -\frac{\partial V_{LJ}}{\partial r} \quad (2)$$

124 The interaction force is the negative of the slope of the plot which depicts the potential energy as a
125 function of the distance. A negative slope corresponds to a repulsive force and a positive slope
126 corresponds to an attractive force. Below a distance of r_{min} , the interaction force will be repulsive and
127 at distances larger than r_{min} , the force between the molecules will be attractive. If $r = r_{min}$, there will be
128 no net force acting on the molecules, as the slope is zero. It has to be noted that the depiction in *Figure*
129 *1* only displays the potential energy of the two molecules and the kinetic energy is not taken into
130 account. Consequently, the plot represents a situation where the molecules have no kinetic energy
131 and are in constant positions to each other, which happens when there is no heat content ($T = 0$ K). If
132 the molecules acquire kinetic energy, by adding heat, the total energy will increase according to the
133 quantity of heat that was added. If V_{LJ} remains below zero, the separation distance will remain finite,
134 and the molecules will oscillate between the two separation distances at that energy level due to the
135 alternation of attractive and repulsive forces (Malick, 2014).

136 It has to be pointed out that the L J-model is straightforward for atoms and simple molecules. However,
137 for more complex organic molecules, where the orientation of the molecules is important, the model
138 is less clear-cut. In this case, the distance between molecules is approximated by the number of
139 molecules in a certain volume unit, which can be described by the density of the material.
140 Nevertheless, it is still a rough approximation for more complex molecules. Therefore, over the years,
141 several alterations of the L J-model have been made in an attempt to improve it, such as for example
142 the Mie potential (Lafitte et al., 2013), the Buckingham potential (Swindells and Sykes, 1938) and the
143 Stockmayer potential (Stockmayer, 1941). The Mie potential is a more generalized case of the LJ
144 potential, where the exponents 12 and 6 are replaced by the more general exponents m and n . The
145 Buckingham potential is a more simplified version of the LJ potential and finally the Stockmayer
146 potential can be defined as an LJ potential where an extra term was added to account for an electric
147 dipole moment. However, the simplicity and often surprising accuracy of the L J-model have
148 contributed to its popularity over the years (Stephan et al., 2020).

149 **2.2. Drug-polymer miscibility and solubility: the influence of interactions**

150 It has been described numerous times that having an ASD homogenously mixed at the molecular level
151 is imperative for its stability (Chan et al., 2015; Meng et al., 2015; Qian et al., 2010; Yuan et al., 2014).
152 When a drug is homogenously distributed in the polymer matrix, the distance between the drug
153 molecules is maximal and the molecules have to travel further in order to aggregate and cause phase
154 separation or crystallization, which requires more energy. Additionally, the polymer chains can provide
155 more steric hinderance and the contact points with the polymer can be optimally used by the drug

156 molecules (Alonzo et al., 2012). It is important to note that most ASDs nowadays have a drug loading
157 where the drug is above the solubility limit in the polymer, meaning that the drug is in a supersaturated
158 state and there is a thermodynamic driving force for phase separation. However, the system can be
159 kinetically stable if the dynamics are slow enough and if the system is below the miscibility limit
160 (Marsac et al., 2006a). Miscibility can be described as the tendency of the supercooled liquid/glassy
161 form of the drug to mix with the polymer. Solubility on the other hand describes the ability of the
162 polymer to act as a solvent for a crystalline drug (Qian et al., 2010). If the drug loading is below the
163 solubility limit, the ASD is thermodynamically stable, and there is no thermodynamic driving force for
164 phase separation. However, the solubility of most small molecules in the polymer is usually quite low,
165 meaning that in most ASDs, the drug is in de supersaturated state (Newman et al., 2012).
166 Consequently, regarding the miscibility of these low molecular weight molecules in a polymer, the drug
167 is in an unstable form with respect to the crystalline state. The miscibility limit is thus a metastable
168 equilibrium, which in fact can be measured for a specific drug-polymer combination. Eventually over
169 time, a miscible drug-polymer system would reach equilibrium with respect to the crystalline drug, and
170 this equilibrium would be the solubility of the drug in the polymer (Malick, 2014). The solubility and
171 miscibility limit of a drug in a polymer, together with data of the glass transition temperature (T_g) can
172 be incorporated in a state diagram, which describes the phase behavior of the ASD as a function of the
173 composition of the ASD and the temperature (Hu et al., 2022). An example of a state diagram can be
174 found in *Figure 2*.

175

176 **Figure 2**

177

178 In order for a drug and polymer combination to form a miscible one-phase ASD system, with respect
179 to thermodynamics, the free energy of mixing (ΔG_{mix}) should be negative. This is represented by
180 equation 3:

$$181 \quad \Delta G_{mix} = \Delta H_{mix} - T\Delta S_{mix}. \quad (3)$$

182 In the equation above, the enthalpy and entropy of mixing are respectively represented by ΔH_{mix} and
183 ΔS_{mix} . These characteristics are dependent on the temperature of the environment and the
184 composition of the mixture. The entropy and enthalpy of mixing can be described in further detail
185 mathematically by the equations (4) and (5) respectively. This allows to understand the phase behavior
186 of ASDs further and explore the factors that influence it. The entropy of mixing can be represented by
187 the following equation(Malick, 2014):

188
$$\Delta S_{mix} = -R(n_d \ln\phi_d + n_p \ln\phi_p), \quad (4)$$

189 Where R is the gas constant, n represents the number of moles of either the drug and the polymer and
 190 ϕ describes the volume fraction of either the drug or polymer in the mixture. Since in a mixture the
 191 volume fraction ϕ of the components is smaller than 1, the logarithms, which are used in the equation,
 192 will be negative. Consequently, the entropy of mixing will always be positive, contributing to a negative
 193 value for ΔG_{mix} , and will always favor mixing over phase separation. This is to be expected, as mixing
 194 increases the disorder of the system, which means that the actual thermodynamic driving force for
 195 either phase separation or mixing is determined by the enthalpy of mixing. The enthalpy of mixing can
 196 be represented by the following equation:

197
$$\Delta H_{mix} = H_{dp} - (H_{dd} + H_{pp}). \quad (5)$$

198 This equation indicates that the enthalpy of mixing is determined by the difference between the
 199 enthalpy of the pure mixture components and the enthalpy of the mixture. Since the entropy of mixing
 200 is relatively large in case of the mixing of a polymer and a small molecule (mainly the contribution of
 201 the API), it allows for a larger disadvantageous enthalpic contribution while still being able to reach
 202 negative free energy of mixing. The enthalpy of mixing will be negative (exothermic mixing) when the
 203 interactions between the drug and polymer are stronger and/or more abundant compared to the
 204 interactions in the pure ASD components. It is also possible that the cohesive interactions present in
 205 the pure components are stronger or similar to those in the ASD, resulting in endothermic or athermal
 206 mixing respectively (Baird and Taylor, 2012a; Malick, 2014).

207 The importance of intermolecular interactions in drug-polymer miscibility can be highlighted by
 208 looking at the approaches that predictive methods use to estimate the miscibility of the components.
 209 The most well-known and popular method to predict drug-polymer miscibility is through the Flory-
 210 Huggins (F-H) lattice theory (Hu et al., 2022). Whereas this theory is based on the free energy in a
 211 polymer-solvent system, a small molecule-polymer system can be considered as analogous and thus
 212 can be described by the F-H theory (Baird and Taylor, 2012a). The Gibbs free energy of mixing of the
 213 system can be calculated based on the position of the molecules in a lattice and on the interactions
 214 between the drug and polymer molecules. The free energy of mixing for an ASD can be characterized
 215 by the following equation:

216
$$\frac{\Delta G_{mix}}{RT} = n_d \ln\phi_d + n_p \ln\phi_p + \chi_{dp} n_d \phi_d \quad (6)$$

217 Where R is the gas constant and T is the absolute temperature. The factor n describes the number of
 218 moles of either the drug or polymer and ϕ describes the volume fraction of the respective component,
 219 whereas χ is the F-H interaction parameter. Upon closer inspection, it becomes apparent that the first

220 two terms of the right-hand side of eq. 6 represent the entropic contribution, as the terms are similar
221 to the terms in eq. 4. Consequently, the third term in the equation represents the enthalpic
222 contribution. As already described, entropy always favors mixing, which means that the enthalpic
223 contribution is the determining factor that decides the thermodynamic favorability of mixing. More
224 specifically, the F-H interaction parameter χ determines whether ΔG_{mix} will become negative for that
225 specific drug-polymer combination. If χ is negative or slightly positive, then the Gibbs free energy of
226 mixing will become negative as well. If χ is positive, then ΔG_{mix} will become positive, and mixing is
227 thermodynamically unfavorable. The F-H interaction parameter is thus an indicator of whether or not
228 the adhesive drug-polymer interactions are stronger or weaker than the cohesive interactions in the
229 pure components (Malick, 2014).

230 A disadvantage of the F-H theory is that it only takes into account nonspecific dispersive interactions
231 and does not account for more specific interactions, such as hydrogen-bonding. This should be taken
232 into consideration when determining χ for a drug-polymer combination that can interact via hydrogen-
233 bonds. For this reason, a modified F-H theory has been suggested to account for systems that can
234 interact via these specific interactions. In the modified F-H theory, an extra free energy term ($\Delta G_H/RT$)
235 can be added, which represents the thermodynamical contribution of the specific interactions. This
236 leads to the following equation:

$$237 \quad \frac{\Delta G_{mix}}{RT} = n_d \ln \varphi_d + n_p \ln \varphi_p + \chi_{dp} n_d \varphi_d + \frac{\Delta G_H}{RT} \quad (7)$$

238 Another more recent approach to estimate solubility and miscibility was developed by Gross and
239 Sadowski, and is a thermodynamic equation of state titled perturbed-chain statistical association fluid
240 theory (PC-SAFT) (Gross and Sadowski, 2001). This equation of state approximates molecules by
241 representing them as chains of spherical segments, and it takes into account multiple specific
242 interactions such as hydrogen bonding. The PC-SAFT equation is generally expressed with respect to
243 the residual Helmholtz energy, accounting for dispersive forces, repulsive forces, association and other
244 interactions such as ionic and dipole-dipole interactions.

245 From the equations above, it can be established that, in terms of thermodynamics, intermolecular
246 interactions play a significant role in the miscibility and solubility of a drug in a polymer matrix. In the
247 following sections, an overview will be provided of the different experimental and theoretical
248 techniques to detect intermolecular interactions, and the influence of these interactions on the
249 physical stability and pharmaceutical performance will be discussed.

250 **3. Methods to probe the microstructure and detect intermolecular**

251 **interactions**

252 The detection of intermolecular interactions between drug and polymer molecules can be performed
253 both in the solid-state and in solution. Nevertheless, in this review, the discussion of the interaction
254 detection methods focusses on the analysis in the solid-state.

255 **3.1. Spectroscopic methods**

256 3.1.1. Fourier transform infrared spectroscopy

257 Infrared spectroscopy is a vibrational spectroscopy method, which allows to measure the vibrational
258 motion of molecules (Christy et al., 2001). These vibrational motions are defined as the repetitive
259 motions which go towards and away from the center of gravity. Molecules that can absorb infrared
260 radiation display a change in the dipole moment during the vibrational motion. Infrared radiation can
261 be absorbed by the molecule if the frequency and energy of the radiation match that which is required
262 for the transition in state. This indicates that the molecular vibrations will transition from the ground
263 state to a more excited state. The measurement of IR spectra is based on this principle of the molecular
264 vibrations and is routinely used to characterize compounds, but also to investigate interactions (Larkin,
265 2017). Traditional IR spectroscopy, where the intensity of each wavelength is checked separately, is
266 used less often nowadays, as it is more time-consuming. Fourier transform infrared spectroscopy (FT-
267 IR) is applied more frequently, where data is collected over a wider range of wavelengths in the form
268 of an interferogram, which is then subsequently Fourier transformed.

269 FT-IR is also frequently used to investigate intermolecular interactions in ASDs. Usually, intermolecular
270 interactions can be detected by observing shifts in the positions of peaks that correspond to interacting
271 functional groups. Hydrogen bonding can for instance be detected by a shift of a C=O group, which is
272 caused by a decrease of the double bonded character due to the hydrogen bond. For example, Dedroog
273 et al. investigated the interactions between naproxen and poly(vinylpyrrolidone-co-vinylacete)
274 (PVPVA) or fenofibrate and PVPVA in different organic solvents in the liquid-state, but also after drying
275 of the solutions in the solid-state films. Via FT-IR measurements, the researchers could establish that
276 naproxen and PVPVA interacted with several organic solvents and that naproxen and PVPVA also
277 interacted with each other to different extents in different solvents. *Figure 3* displays the FT-IR spectra
278 of mixtures of PVPVA and naproxen in various solvents. The shoulder peak in the VP carbonyl stretching
279 signal around 1636 cm^{-1} indicated the existence of hydrogen bonds between naproxen and PVPVA. It
280 could be observed that stronger interactions were present in acetonitrile and dichloromethane
281 compared to the other alcoholic solvents, as the shoulder peak already was present for the lowest

282 naproxen concentration of 10 wt% in acetonitrile and dichloromethane. Additionally, hydrogen bonds
283 between drug and polymer could be observed as well in the films after drying of the solutions (Dedroog
284 et al., 2022). Kothari et al. used FT-IR to evaluate the strength of hydrogen bonds between nifedipine
285 and three different polymers, polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose acetate
286 succinate (HPMCAS) and poly(acrylic acid) (PAA). It was observed that the strength of the
287 intermolecular interactions with nifedipine were ranked in the following order: PVP > HPMCAS > PAA.
288 Additionally, dielectric spectroscopy and X-ray powder diffraction (XRPD) were performed to
289 investigate molecular mobility and crystallization kinetics respectively (Kothari et al., 2015a).

290 **Figure 3**

291 Chen et al. used FT-IR to investigate intermolecular interactions between several compounds and
292 different polymers in ASDs before and after exposure to moisture. The compounds used in this study
293 were felodipine, ketoconazole and griseofulvin, and the polymers were PVPVA and HPMCAS. For the
294 ketoconazole ASDs, they could link drug release to the strength of the intermolecular interactions, as
295 the ketoconazole/HPMCAS ASDs showed a faster drug release than the ketoconazole/PVPVA ASDs.
296 The researchers explained that the difference in drug release could partially be attributed to a
297 difference in intermolecular interaction strength, together with the lower crystallization tendency of
298 ketoconazole and the ability of HPMCAS to maintain supersaturation (Y. Chen et al., 2015a). It was
299 observed that the stronger ketoconazole/HPMCAS interactions lead to a higher degree of
300 supersaturation and a stronger resistance of the interactions to disruption by water. FT-IR and
301 attenuated total reflectance (ATR) -FT-IR, are one of the most applied methods to detect
302 intermolecular interactions, due to the ease and speed of the measurements. Interpretation of the
303 spectra can be straightforward, although it is sometimes hard to distinguish peaks shifts for
304 overlapping peaks and interpret the observed changes.

305 3.1.2. Raman spectroscopy

306 Raman spectroscopy is another vibrational spectroscopy technique, similar to infrared spectroscopy,
307 though it yields complementary information, as it relies on inelastic scattering of photons. Usually,
308 monochromatic light is used to radiate the sample. The photons will interact with the molecular
309 vibrations of the sample molecules, which results in the energy of the photons being shifted either
310 up or down. These shifts yield information about the vibrational modes of the molecule. Note that
311 only molecules who display a change in their polarizability are Raman active (as opposed to IR, which
312 reflects changes in the dipole moment of molecules) (Larkin, 2017; Vankeirsbilck et al., 2002). Similar
313 to IR, changes in the chemical environment will be reflected in the Raman spectrum through changes
314 in the peak position or peak shape, or by the appearance of new peaks (Palermo et al., 2012). It also

315 has been described that Raman may be more suited to detect non-specific interactions (e.g.
316 hydrophobic interactions) in drug-polymer systems, which are rich in aromatic groups (Rawlinson et
317 al., 2007). This is due to its working principle, which is based on changes in polarization.

318 An example of Raman spectrometry being used to investigate intermolecular interactions can be found
319 in the work of Keratichevanun et al. (Keratichevanun et al., 2015) where the researchers used Raman
320 spectrometry and IR spectrometry to investigate the miscibility and intermolecular interactions
321 between components in nifedipine-Soluplus® ASDs, which were produced using different
322 manufacturing techniques. It was found that the drug interacted with Soluplus® via hydrophilic and
323 hydrophobic interactions. The hydrophilic interactions could be identified using IR and the
324 hydrophobic interactions were observable via Raman spectroscopy. Peak shifts could be seen for
325 nifedipine in the spectral region of 790 to 820 cm⁻¹, which is characteristic for aromatic hydrocarbons
326 (Keratichevanun et al., 2015; Rawlinson et al., 2007).

327 Additionally, Lu and Cuellar et al. (Lu et al., 2016) also investigated the formation of intermolecular
328 interaction between felodipine using various techniques, including FT-IR and Raman spectroscopy.
329 They reported a Raman peak shift that was observed in the region of 1200-1700 cm⁻¹, which was a
330 potential indication of intermolecular interactions. Following theoretical calculations, it became clear
331 that the shifted Raman peaks corresponded to C-H bending, N-H bending and a combination of C-C
332 and N-H bending peaks. Consequently, the shifts in these Raman peaks indicate the formation of
333 hydrogen bonds(Lu et al., 2016).

334 Admittedly, Raman spectroscopy is for many researchers often not the technique of first choice to
335 investigate intermolecular interactions. Of the vibrational spectroscopic techniques, FT-IR is more
336 popular for this purpose, despite the fact that Raman Spectroscopy can be used for samples dissolved
337 in water, which is not the case for IR. Raman spectroscopy is rather used to investigate phase
338 separation or to detect crystallinity in the ASD(X. Chen et al., 2015; Dohrn et al., 2021; Netchacovitch
339 et al., 2017) . Additionally, Raman mapping is often used as well to examine the phase behavior of
340 ASDs (Krummnow et al., 2023; Luebbert et al., 2018; Meng et al., 2015) or confocal Raman microscopy
341 as well, which is a combination of traditional light microscopy and Raman spectroscopy. This technique
342 provides chemical information of a certain region of interest in the sample. With respect to ASDs, it
343 has for example been used to investigate changes in the phase behavior of the ASDs upon contact with
344 water (Punčochová et al., 2016).

345 3.1.3.Solid-State nuclear magnetic resonance

346 Solid-state nuclear magnetic resonance (ssNMR) can be considered as one of the most versatile and
347 accurate techniques in the toolbox of a formulation scientist, especially for the elucidation of the

348 physical structure of ASDs. A detailed description of the working mechanism of ssNMR is beyond the
349 scope of this review but is thoroughly discussed in dedicated literature(Duer, 2004; Levitt, 2015). With
350 respect to the solid-state characterization of ASDs, ssNMR can have multiple applications, ranging from
351 detecting crystallinity and other solid forms of drug candidates, probing molecular miscibility,
352 molecular dynamics, intra- and intermolecular interactions etc. (Kruk et al., 2012) With respect to
353 investigating intra- and intermolecular interactions, ssNMR is often the technique of choice when it
354 comes to exploring the type, strength and extent of different homo- and heteronuclear noncovalent
355 intermolecular interactions. These interactions can range from ionic to dipolar and hydrogen bonding
356 (Vogt et al., 2011)(Vogt et al., 2011).

357 The most straightforward and popular method to detect drug-polymer intermolecular interactions is
358 by observing spectral alterations like peak shifts (upfield or downfield, due to shielding or deshielding)
359 or peak broadening in the one-dimensional spectrum of the ASD compared to the peaks in the spectra
360 of the pure ASD components. These spectral alterations are the result of changes in the local chemical
361 environment of the nuclei, which are inflicted by the interactions. The ^{13}C nucleus is used most often
362 for these types of experiments due to the wider resonance frequency range, which makes it easier to
363 observe and interpret spectral changes, compared to for example the ^1H nucleus, which has a narrower
364 isotropic resonance region. Many researchers have investigated the intermolecular interactions in
365 ASDs by comparing peak positions in one dimensional (1D) ^{13}C spectra, which are measured most often
366 via cross-polarization magic angle spinning (CP/MAS) experiments (Mistry et al., 2015; Okada et al.,
367 2020; Pugliese et al., 2021; Song et al., 2015). Other nuclei, which are prominent in a lot of APIs, such
368 as ^{19}F , ^{15}N or ^{17}O are also used in this regard and can provide additional complementary information.
369 An example of this can be found in the work of Song et al. where the researchers performed ^{15}N CPMAS
370 NMR to investigate the protonation state of lapatinib in ASDs with various polymers. In the ^{15}N -spectra
371 of the ASD with hydroxypropyl methylcellulose phthalate (HPMCP), it was observed that there were
372 two nitrogen populations for the amine group, which almost certainly corresponded to ionized and un-
373 ionized lapatinib (*Figure 4*). This indicated that salt formation occurred between lapatinib and HPMCP,
374 whereas no salt formation was observed with the other polymers (Song et al., 2015).

375

376 **Figure 4**

377

378 Besides the standard one-dimensional NMR experiments, multi-dimensional NMR experiments are not
379 only a great tool for structural characterization but can also be applied in the investigation of
380 intermolecular interactions and miscibility of the ASD components. The most commonly used two-

381 dimensional NMR techniques can roughly be divided in two main categories: correlation experiments
382 and separation experiments (Paudel et al., 2014). In the correlation experiments, the correlations
383 between either homo- or heteronuclear pairs originate from the coupling via dipolar or scalar
384 interactions and are a reflection of the spatial proximity of the nuclei (either through space or through
385 bonds). The most commonly used solid-state 2D NMR techniques are HETCOR, INEPT, MAS-J-HSQC,
386 INADEQUATE, DQ/SQ, etc. The second type of experiments have as a goal to measure specific
387 anisotropic interactions and include techniques that allow the measurement of chemical shift
388 anisotropy, dipolar coupling or quadrupolar coupling. A large variety of different two-dimensional
389 techniques to investigate intermolecular interactions exist and discussing them all would extend
390 beyond the focus of this paper. Readers interested in this topic can be referred to a detailed review on
391 solid-state NMR for ASDs by Paudel et al. (Paudel et al., 2014).

392 An example of applying a two-dimensional NMR technique to investigate intermolecular interactions
393 can be found in a paper by Lu et al. from 2019 where they performed 2D ^{13}C - ^1H HETCOR NMR to
394 investigate the interactions between posaconazole and HPMCAS (Lu et al., 2019). The experiments
395 revealed a correlation between the triazole group of posaconazole and the hydroxyl group of HPMCAS,
396 which suggested that these functional groups were in close proximity to each other and formed
397 hydrogen bonds. Additionally, another intermolecular contact was detected by utilizing ^{13}C - and ^{15}N -
398 labeled posaconazole and performing 2D ^{13}C - ^1H HETCOR NMR on the samples. A correlation was
399 observed between the carbonyl of posaconazole and the carboxyl group of HPMCAS, which pointed in
400 the direction of a drug-polymer interaction. Consequently, the combination of multiple NMR
401 techniques allowed the elucidation of two types of interactions between posaconazole and HPMCAS
402 (Lu et al., 2019). Improved miscibility is often a consequence of the presence of intermolecular
403 interactions, and the assessment of the miscibility of ASDs is regularly performed via ssNMR
404 relaxometry measurements. the proton spin-lattice relaxation time ($T_{1\text{H}}$) and the proton spin-lattice
405 relaxation decay time in the rotating frame ($T_{1\rho\text{H}}$), which are related to the process of spin diffusion,
406 are associated with the domain size of phase separated domains. The maximum path length over which
407 proton-proton spin diffusion can occur, can be described by $L \sim (6DT_{\text{iH}})^{1/2}$, where D denotes the spin
408 diffusion coefficient ($\sim 4\text{-}6 \times 10^{-16} \text{ m}^2/\text{s}$ for solids) and T_{iH} represents the relaxation time (either $T_{1\text{H}}$ or
409 $T_{1\rho\text{H}}$). If the domain size exceeds the maximum path length for spin diffusion, then separate relaxation
410 times will be measured for each of the mixture components. On the other hand, if the domains are
411 smaller than the maximum path length, a similar relaxation time will be measured for each of
412 components (Mehring, 1996; Wang et al., 2002, 2001). ssNMR relaxometry is often combined with
413 other ssNMR spectrometric techniques in the characterization of the physical structure of ASDs.

414

415 Herein lies one of the key strengths of solid-state NMR, besides the high accuracy and robustness. The
416 possibility of combining multiple one-dimensional and multi-dimensional NMR techniques and
417 investigating different nuclei, often allows for an in-depth and detailed picture of the intermolecular
418 interactions, miscibility and physical structure of the ASD. This often makes solid-state NMR the
419 technique of choice when it comes to investigating intermolecular interactions. However, it also should
420 be noted that equipment can be relatively expensive and measurement times can be quite long.
421 Additionally, interpretation of the data and performing experiments correctly requires specific
422 expertise.

423 3.1.4. X-ray photoelectron spectroscopy

424 X-ray photoelectron spectroscopy (XPS) is a surface-sensitive analysis technique, which allows to probe
425 the elemental composition of the first 10 nm of a solids outer surface (van der Heide, 2011). The
426 technique can detect all elements from Lithium until uranium except for H and He, which are not
427 detectable with XPS. Not only the elemental composition can be detected, but XPS can give an
428 indication of the chemical environment of those respective elements (van der Heide, 2011). This
429 surface analysis technique works by irradiating a sample with monochromatic x-rays in order to excite
430 atoms, which in turn release photoelectrons, often referred to as the 'photoelectric effect'. The kinetic
431 energy of the released photoelectrons is determined and subsequently, the binding energy is
432 calculated, which is a characteristic that is specific for each element, allowing identification of specific
433 elements on the surface (van der Heide, 2011).

434 With regard to ASDs, XPS is most often used to examine the composition of a particle surface in terms
435 of drug to polymer ratio. An example of this can be found in the work of Borchardt-Setter et al.
436 (Borchardt-Setter et al., 2024) where XPS was used to investigate the surface composition of two
437 ternary ASDs containing posaconazole, PVP K12 and Span 80 or posaconazole, PVPVA and Span 80. It
438 was found that, despite being miscible in the bulk of the formulation, XPS measurements revealed that
439 posaconazole was depleted from the surface.

440 XPS is less often applied as a tool to investigate intermolecular interactions compared to other
441 spectroscopic techniques such as FT-IR and ssNMR. Nevertheless, it can still be used with this goal in
442 mind, as was proven by for example Trasi et al. (Trasi et al., 2020). In this study, XPS was used to
443 examine the protonation of lumefantrine in ASDs with several different polymers. It was found that
444 the basic compound lumefantrine underwent salt formation with acidic polymers, which was
445 demonstrated by the appearance of an additional N 1s peak around 402 eV, corresponding to the
446 protonated nitrogen of lumefantrine. Varying degrees of salt formation could be detected with respect
447 to the polymer that was used in the formulation of the ASD. The interactions between lumefantrine

448 and the polymers were corroborated by FT-IR measurements, where peak shifts were detected in the
449 carbonyl region of the polymers (Trasi et al., 2020). Other examples exist where researchers observed
450 hydrogen bonding (González Cortes et al., 2023; Maniruzzaman et al., 2015) and π - π stacking (González
451 Cortes et al., 2023) between the components via XPS measurements. Admittedly, XPS is not the first
452 technique of choice when it comes to probing intermolecular interactions, as it only provides
453 information on the surface and not the bulk of the material and some issues have been reported with
454 the reproducibility of the measurements (Pinder et al., 2024). Other techniques, which are applied
455 more often with the aim to investigate intermolecular interactions, allow to acquire more detailed
456 information about the types of interactions in the ASD.

457

458 3.2. Other methods

459 3.2.1. (modulated) differential scanning calorimetry

460 With respect to ASDs, (modulated) differential scanning calorimetry (mDSC) is mostly used to
461 investigate drug-polymer miscibility, probe the crystallinity in the formulation or assess the solubility
462 of the drug in the polymer matrix (Dedroog et al., 2020). However, some information on the
463 intermolecular interactions between drug and polymer can still be distilled from mDSC experiments,
464 although this is limited. For a certain binary drug-polymer combination, it is possible to estimate the
465 T_g of the final ASD for different drug-polymer ratios by using the Gordon-Taylor equation (Gordon;
466 Taylor, 1952):

$$467 T_g = \frac{K_1 T_{g1} + K_G W_2 T_{g2}}{W_1 + K_G} \quad (8)$$

468 Where T_g , T_{g1} and T_{g2} are the glass transition temperatures of the final ASD, the amorphous drug and
469 the polymer respectively. W_1 and W_2 are the weight fractions of the drug and polymer respectively. K_G
470 is a constant which can be calculated using the equation below:

$$471 K_G \approx \frac{\rho_1 T_{g1}}{\rho_2 T_{g2}} \quad (9)$$

472 In this equation ρ_1 and ρ_2 represent the densities of the amorphous drug and the polymer respectively,
473 and T_{g1} and T_{g2} are the glass transition temperatures of the amorphous drug and the polymer, which
474 are the same as in the Gordon-Taylor equation. Besides the Gordon-Taylor equation, other equations
475 are also used to estimate the T_g of the resulting ASD, such as the Fox (Fox, 1952) or Kwei (Kwei, 1984)
476 equation. Nevertheless, the Gordon-Taylor equation is considered to be the most popular equation to
477 estimate the glass transition temperature. The estimation of T_g according to the Gordon-Taylor
478 equation assumes that ideal mixing takes place and that the strength of the drug-polymer interactions

479 is similar to the homomolecular interactions in the pure separate components. However, sometimes
480 experimental T_g values can deviate significantly from the theoretical ones (Baghel et al., 2016b).
481 Positive or negative deviations can occur due to heteromolecular interactions between drug and
482 polymer being either stronger or weaker than the homomolecular interactions (Baghel et al., 2016b).
483 Therefore, a positive deviation from the T_g values estimated via the Gordon-Taylor equation can
484 indicate that strong intermolecular interactions are present between the drug and polymer in the ASD
485 (See *Figure 5*) for a graphical presentation). A negative deviation, on the other hand, suggests that the
486 homomolecular interactions are stronger than the drug-polymer interactions as a lower T_g indicates
487 that less energy is required to increase the mobility to form the supercooled liquid. Admittedly,
488 deviations from the ideal mixing behavior only provide qualitative information about whether or not
489 some kind of interactions are present, and not which types of interactions it encompasses.
490 Additionally, deviations are not always the direct result of intermolecular interactions, and it is also
491 possible that intermolecular interactions may not lead to deviations from the predicted T_g values (Baird
492 and Taylor, 2012b). Therefore, caution is advised when interpreting interactions via deviations of the
493 predicted T_g values via the Gordon-Taylor equation.

494

495 **Figure 5**

496

497 Researchers have used this approach to investigate the possibility of interactions between the APIs
498 sorafenib and regorafenib, and the polymers PVP and PVPVA (Liu et al., 2019). It was found that the
499 experimental T_g values of the ASDs containing sorafenib showed a positive deviation from the
500 predicted values, whereas the regorafenib ASDs displayed a negative deviation or matched the
501 estimated values. This indicated that intermolecular interactions between the polymers and sorafenib
502 were stronger compared to those with regorafenib. These findings were then subsequently
503 corroborated by solution NMR and computational methods (Liu et al., 2019).

504 3.2.2. Dynamic vapor sorption

505 Dynamic vapor sorption (DVS) is a gravimetric analysis technique, which is routinely used to investigate
506 how much solvent is sorbed by a solid sample. This is usually done by measuring the changes in mass
507 of the sample as a function of the changing vapor concentration in the environment at a constant
508 temperature. Water is mostly used as a solvent for this technique, although other organic solvents can
509 be used as well (Hunter, 2016). Moisture sorption experiments can give insight into the moisture
510 sorption properties of the material, which is a crucial factor in determining the stability and processing

511 characteristics of that material. Additionally, water vapor sorption measurements can also be applied
512 to investigate the formation of solvates (Burnett et al., 2007) or hydrates (Vogt et al., 2006).

513 Although DVS is not a technique that first comes to mind with respect to investigating the interactions
514 in ASDs, it has been applied in this regard by Punčochová et al. (Punčochová et al., 2014). In this work,
515 the authors tried to relate deviations from the additivity of water sorption isotherms of individual
516 components to intermolecular interactions in the ASDs. When predicting water sorption curves of
517 binary mixtures, additivity of the individual component isotherms is assumed and can be described by
518 the following equation:

$$519 \quad W_{mixture} = \frac{(W_{API} m_{API} + W_{polymer} m_{polymer})}{(m_{API} + m_{polymer})} \quad (10)$$

520 Where W is the mass of the absorbed solvent for each specific dry component and m is the mass of
521 the respective component in the mixture (Kachel et al., 2013). A deviation from this ideal additivity
522 behavior can be interpreted as an indication of intermolecular interactions between drug and polymer
523 and the intensity of the deviation as a sign of the strength of the interactions. The researchers
524 measured the water sorption isotherms for ASDs containing valsartan and either PVP K30, Soluplus or
525 Eudragit. The ASDs with PVP and Soluplus showed a significant negative deviation from the ideal
526 isotherms as according to equation 10. The ASD containing valsartan and Eudragit displayed a positive
527 deviation from the ideal isotherm, and thus had an increased water sorption. The results from the
528 water sorption measurements could be correlated to the observations made in the ATR-FT-IR analysis.
529 It was shown that in the ASDs containing PVP and Soluplus, the C=O peak of valsartan, which usually
530 appears around 1605 cm⁻¹, displayed a shift to lower wavenumbers, indicating interactions between
531 the drug and polymer. For the ASD containing Eudragit, a shift to a higher wavenumber was observed.
532 The differences in interactions between valsartan and the polymers also translated to different
533 dissolution profiles for the ASDs (Punčochová et al., 2014). Similar approaches have been applied by
534 other researchers as well after this study (Baghel et al., 2016c).

535 Similar to mDSC, the use of DVS to investigate intermolecular interactions only provides an indication
536 that intermolecular interactions might be present in the sample and can supply a measure for the
537 extent of the strength of the interactions. However, it provides no qualitative information about what
538 type of interactions might be present in the sample. Nevertheless, DVS can still be used as a
539 complementary technique to provide additional evidence for the formation of intermolecular
540 interactions.

541 3.2.3.X-ray atomic pair distribution function

542 The pair distribution function (PDF) of X-ray scattering patterns can be obtained via Fourier
543 transformation and although it does not probe intermolecular interactions in the true sense of the
544 word, it can reveal information about long-range and short-range structural correlations between
545 molecules(Billinge and Jensen, 2023; Terban and Billinge, 2022). The PDF method gives an indication
546 of the probability of finding an atom at a certain distance of the origin point (Chen et al., 2021). PDF
547 analysis can be used for a very wide variety of applications (Terban and Billinge, 2022) of which the
548 discussion would go beyond the scope of this review. Nevertheless, some of the potential and most
549 popular applications are for example, the determination of the molecular crystal structure (David and
550 Shankland, 2008), phase quantification (Chen et al., 2001), the study of component miscibility (Chieng
551 et al., 2013), measuring impurities (Terban et al., 2015), etc.

552 Although PDF of X-ray scattering data is not generally used for the investigation of intermolecular
553 interactions in ASDs, Chen et al. (Chen et al., 2023) have applied X-ray PDF in combination with ssNMR
554 and principal component analysis in order to evaluate the molecular structure of amorphous
555 posaconazole and investigate the intermolecular interactions in ASDs with posaconazole and HPMCAS.
556 Next to characterizing the molecular structure of crystalline and amorphous posaconazole, the
557 researchers measured changes in the nearest neighbor peak in the PDF analysis of the X-ray diffraction
558 data of the ASD as a function of the drug loading. Additionally, peak shifts for several carbon peaks of
559 HPMCAS and posaconazole in the ^{13}C ssNMR spectra of the ASDs were observed with respect to the
560 drug loading. The PDF results and peak shifts in the ^{13}C spectra were both incorporated in a PCA
561 analysis. It was found that a similar trend of the first principal component was seen for both the PDF
562 data and the ssNMR data, which indicated that both methods successfully displayed a monotonic
563 change in the drug-polymer interactions as a function of the drug loading (Chen et al., 2023).
564 Previously, another research group was also able to identify ion pair interactions in ASDs containing
565 lapatinib and HPMC-E3 (De Araujo et al., 2017). This was done by extracting the intra- and
566 intermolecular lapatinib and polymer functions from the total structure factors of pure lapatinib and
567 polymer. Subsequently, the contributions of the polymer and the intramolecular lapatinib structure
568 factors were subtracted, leaving the contributions of the drug-drug and drug-polymer interactions (De
569 Araujo et al., 2017).

570 As a stand-alone technique to investigate intermolecular interactions, the PDF method is not an ideal
571 option, as the interpretation of the diffraction patterns is often challenging. Intra- and intermolecular
572 distances can overlap, which can further complicate interpretation of the peaks (Chen et al., 2021).
573 The PDF method also only detects the proximity of atoms, and it is difficult to distil information about
574 interactions from it. Nevertheless, a combination of X-ray PDF analysis and other complementary

575 methods (such as ssNMR) can provide a significant advantage in interpreting the molecular structure
576 of ASDs.

577 **3.3. *In silico* predictions of interactions**

578 A large amount of different *in silico* simulation methods and molecular modeling approaches have
579 been developed in recent years, which can be used for a variety of purposes. With respect to ASDs,
580 and simulating drug-polymer intermolecular interactions more specifically, three types of simulations
581 are mainly used: docking studies, molecular dynamics and quantum mechanics (Nambiar et al., 2022).
582 Within these simulation types, there is still a wide array of experiments which are available with
583 different aims in mind. A more in-depth explanation of the different types of molecular modeling
584 approaches which are used to investigate the various properties of amorphous solid dispersions can
585 be found in a review by Nambiar, Singh and Mali et al. (Nambiar et al., 2022).

586 The two main computational simulations, which are routinely used to investigate interactions between
587 ASD components, are docking studies and molecular dynamics. Molecular docking simulations can be
588 used to generate preliminary binding confirmations and predict the binding affinity between drug and
589 polymer. Generally, if the calculated binding affinity between the two components is negative, then
590 this a good indication that intermolecular interactions will be present in the physical ASD (Barmpalexis
591 et al., 2019). Docking studies have been used in a number of recent investigations to simulate
592 intermolecular interactions in ASDs (Budiman et al., 2022; Rosiak et al., 2024; F. Zhang et al., 2022). An
593 example of this can be found in a study conducted by Rosiak et al. where the researchers investigated
594 ASDs consisting of myricetin and PVP K30 (Rosiak et al., 2024). Molecular docking simulations, which
595 were conducted by use of the Autodock 4.0 software, implied that hydrogen bonds were formed
596 between the O-H group of myricetin and the C=O group of PVP K30. The existence of these hydrogen
597 bonds was confirmed by analyzing the samples with FT-IR as well (Rosiak et al., 2024).

598 Molecular dynamics, on the other hand, provides a tool to simulate the movement of all molecules in
599 a complex system, such as an ASD, as a function of time, based on the physics that dictate the
600 intermolecular interactions (Karplus and McCammon, 2002). This tool requires that the components
601 of the system are parametrized by a force field that appoints the total energy of the system as a sum
602 of potential energy functions (Ma et al., 2020). Different types of force fields exist, which all describe
603 the energy of the system depending on the position of the atoms. Molecular dynamics simulations
604 have been applied in multiple studies investigating the intermolecular interactions in ASDs (Aulifa et
605 al., 2024; Becelaere et al., 2022; Kbedev et al., 2022). Becelaere and Van Den Broeck et al. (Becelaere
606 et al., 2022) used molecular dynamics simulations to investigate drug-polymer interactions between
607 flubendazole and poly(2-ethyl-2-oxazoline) (PEtOx). The researchers constructed customized force

608 fields for both flubendazole and PEtOx, which were then validated as well. It was observed in the
609 molecular dynamics simulations that hydrogen bonds were present between flubendazole and PEtOx,
610 and that there was a competition for hydrogen bond donor sites, which was dominated by PEtOx. The
611 simulated hydrogen bonds were also confirmed to be present in the experimentally electrospun ASDs
612 by ATR-FT-IR (Becelaere et al., 2022). In this study, a second computational method was used to
613 simulate the interactions that would occur in the ASDs, namely density functional theory (DFT)
614 calculations, which belong to the third and final group of *in silico* methods.

615 The final type of computational methods which can be used to study intermolecular interactions is
616 quantum mechanics, of which DFT calculations are an often-applied example, like it was used in the
617 example in the paragraph above. DFT calculations allow for the investigation of non-bonding
618 interactions via the construction of molecular complexes and the associated interaction energy
619 (Mazurek et al., 2020). It is a rapid and powerful technique, which provides a 'static snapshot' of the
620 molecular complexes (Nambiar et al., 2022) and is used as a computational approach in a variety of
621 studies (Sarpal et al., 2019; Wang et al., 2017; S. Zhang et al., 2022). In one such study, Wang et al.
622 used DFT calculations to predict interactions between PVP and resveratrol or griseofulvin (Wang et al.,
623 2017). It was predicted that hydrogen bonds would be formed between PVP and resveratrol, and the
624 distances of the hydrogen bonds were calculated as well. It was verified by FT-IR analysis that in the
625 ASD, hydrogen bonds between PVP and resveratrol could indeed be observed (S. Zhang et al., 2022).

626 Of course, it has to be mentioned that the *in silico* simulations of intermolecular interactions are, in
627 fact, obviously only predictions and are not a real reflection of the actual interactions that exist in the
628 physical ASDs. Therefore, most studies that apply computational methods to simulate the interactions
629 that could occur between ASD components, also utilize other methods to verify the predictions
630 experimentally. Most often, these predictions are complemented with spectroscopic measurements
631 such as ssNMR or FT-IR. Nevertheless, molecular modeling approaches can hold a significant benefit
632 for researchers investigating intermolecular interactions, as the predictions can give useful insights
633 into the functional groups that are involved in the interactions, help with the interpretation of other
634 results or confirm observations made with other techniques.

635 **4. Influence of intermolecular interactions on the physical stability**

636 It is one thing to be able to detect intermolecular interactions in an ASD system, but the knowledge of
637 interactions only holds real value if it is understood how these molecular interactions affect important
638 end-product properties, such as the physical stability and the pharmaceutical performance. Obviously,
639 the stability and dissolution of ASDs are very complex processes, which depend on a range of different
640 factors besides intermolecular interactions. Nevertheless, drug-polymer interactions still play an

641 important role in both of these processes and it is crucial to understand every step and aspect of the
642 process to be able to fully comprehend what exactly is occurring and how all steps are connected.
643 Therefore, in this section and the next one, the influence of the drug-polymer interactions on the
644 physical stability and the drug release from ASDs will be discussed.

645 The physical stability of an ASD can be defined as the ability of the system to maintain its amorphous
646 nature, while remaining a one-phase molecularly mixed dispersion. (Newman et al., 2012)(Bhujbal et
647 al., 2021b)With respect to the physical stability of ASDs, several factors play a key role in determining
648 the stability of the formulation upon storage. The loading of the drug with respect to drug-polymer
649 solubility and miscibility (Chan et al., 2015; Meng et al., 2015; Qian et al., 2010; Yuan et al., 2014), the
650 crystallization tendency of the drug (Van Eerdenbrugh et al., 2010), the T_g of the ASD system with
651 respect to the storage temperature(Yoshioka et al., 1994), the humidity of the environment
652 (Rumondor et al., 2009) and the presence of drug-polymer intermolecular interactions, of which the
653 influence will be discussed below.

654 Intermolecular interactions can influence the stability of ASDs in a variety of ways. As already discussed
655 in the first section of this review, drug-polymer interactions can have a positive influence on the
656 solubility and miscibility of drug and polymer (Bookwala and Wildfong, 2023). Multiple studies have
657 already indicated that the drugs which interact with the polymer, have an improved solubility in those
658 polymers compared to their solubility in polymers with less potential for intermolecular interactions
659 (Bookwala et al., 2022; Knopp et al., 2015; Tao et al., 2009). Similar to the solubility, the drug-polymer
660 miscibility can also be improved by the existence of intermolecular interactions, as was proven by
661 Marsac et al. who investigated mixing between felodipine and nifedipine with PVP (Marsac et al.,
662 2006b). The researchers could correlate the interaction potential of the two APIs and PVP with the
663 miscibility data of the two systems that were obtained in previous studies.

664 Besides improving solubility and miscibility of the drug in the polymer, intermolecular interactions can
665 also alter the molecular mobility of the drug molecules in the polymer matrix (Bookwala and Wildfong,
666 2023; Kapourani et al., 2021). Generally, the higher T_g of the polymer compared to that of the
667 amorphous API increases the T_g of the overall ASD system, leading to an antiplasticizing effect and a
668 decreased molecular mobility of the API in the ASD (Baghel et al., 2016b). The reduced molecular
669 mobility lowers the chance of AAPS and nucleation/crystallization, as the movement of the drug
670 molecules is hampered (Yao et al., 2020). Drug-polymer intermolecular interactions can result in an
671 additional reduction of the molecular mobility of the drug molecules in the ASD system, by decreasing
672 the degrees of freedom of the API (Aso and Yoshioka, 2006) and also reducing the global mobility of
673 the total ASD system (Bhardwaj et al., 2014). This was for instance established in a study by Kothari et

674 al. where the strength of the intermolecular interactions between nifedipine and three different
675 polymers was correlated with the molecular mobility and the crystallization kinetics (Kothari et al.,
676 2015b). It was found that the strongest drug-polymer interactions could be observed between
677 nifedipine and PVP, which resulted in the largest increase in the relaxation times and the highest
678 reduction of the crystallization kinetics (Kothari et al., 2015b). As a demonstration of this, the dielectric
679 loss of ASDs containing nifedipine and one of three selected polymers (PVP, PAA and HPMCAS) is
680 depicted in *Figure 6*. The dielectric loss peak for the nifedipine-PVP ASD occurred at a much lower
681 frequency compared to the other polymers, indicating a higher reduction of the mobility.

682 **Figure 6**

683 Lastly, drug-polymer interactions can also reduce the risk of nucleation and crystallization of the API in
684 the polymer matrix, beyond the effect of reducing molecular mobility. As already mentioned, if the
685 drug loading of the API in the ASD is above the drug-polymer solubility, then there is a thermodynamic
686 driving force for phase separation and crystallization, as the system is considered a metastable state
687 compared to the crystalline counterpart. The formation of a critical nucleus, the first step in the
688 crystallization process, is associated with an increase in the free energy and the smaller this energy
689 barrier is, the higher the chance of forming that critical nucleus is (Rams-Baron et al., 2018). If drug-
690 polymer interactions are present, then first of all, the free energy of the system is reduced, decreasing
691 the driving force for phase separation (Malick, 2014). Additionally, the energy barrier that needs to be
692 overcome in order for the drug molecules to come together and phase separation to occur is increased,
693 as these intermolecular interactions need to be disrupted for that to happen (Krishna Kumar and
694 Suryanarayanan, 2022). Zhang et al. showed, for example, that the nucleation rates of fluconazole
695 were significantly decreased by HPMCAS and were attributed to strong intermolecular interactions
696 and the larger monomer unit (Zhang et al., 2021). PVP K30, on the other hand, only had a minor
697 inhibitory effect on the nucleation of fluconazole and poly (ethylene oxide) (PEO) even resulted in an
698 increase of the nucleation rates (Zhang et al., 2021). Not only nucleation can be inhibited by the
699 presence of drug-polymer interactions, but the crystal growth after nucleation can also be affected by
700 the interactions. In a study by Kestur and Taylor, a correlation was observed between the crystal
701 growth rate of amorphous felodipine and the strength of the drug-polymer interactions between
702 felodipine and the polymers that were selected (Kestur and Taylor, 2010). The order of crystallization
703 inhibition effectiveness was PVP > PVPVA > HPMCAS > PVAc, and the same order was observed with
704 respect to the strength of the hydrogen bonding interactions between felodipine and the polymers.
705 Consequently, it appeared that polymers which can form stronger interactions with the API inhibit
706 crystallization to a larger extent (Kestur and Taylor, 2010).

707 A good example of the influence of intermolecular interactions on the stability of ASDs can be found
708 in the comparison study of Wu and Van den Mooter (Wu and Mooter, 2023) where ASDs were
709 manufactured with PVPVA and six different APIs. The APIs could be subdivided according to their
710 crystallization tendency as a slow, moderate or fast crystallizer. In each crystallization category, an API
711 with and without hydrogen bond donor groups was placed and for each API the maximum drug loading
712 was determined in PVPVA and a stability study was performed on the respective ASDs. It was found
713 that, in the same class of crystallization tendency, the APIs which contained hydrogen bond donor
714 groups attained higher possible drug loadings compared to the drugs without donor groups (Wu and
715 Mooter, 2023). Additionally, the ASDs which contained APIs that had hydrogen bond donor groups
716 remained stable for a longer period of time compared to the APIs which did not contain hydrogen bond
717 donor groups.

718 In conclusion, with respect to the physical stability of ASDs, intermolecular interactions play a very
719 important role. Drug-polymer interactions can improve the solubility of the drug in the polymer and
720 the drug-polymer miscibility, which can lead to higher possible drug loadings as well. Besides this,
721 interactions can reduce the molecular mobility of the drug in the polymer matrix. Lastly, intermolecular
722 interactions can reduce the chance of nucleation and can slow down crystal growth kinetics
723 significantly, which all leads to an improved physical stability. Interestingly, when it comes to spray
724 dried ASDs or ASDs manufactured with other solvent-based techniques, it has been observed that
725 drug-polymer interactions and conformations in solution can be transferred to the solid-state (Defrese
726 et al., 2020). Interactions with the solvent are also of importance, thus the solvent that is used to
727 manufacture the ASDs can impact properties of the ASDs in the solid-state as well (Dedroog et al.,
728 2022).

729 **5. Influence of intermolecular interactions on dissolution and** 730 **supersaturation**

731 Besides the physical stability upon storage, another important property of ASDs is the release profile
732 of the drug from the formulation. As it is the aim of ASDs to improve the oral bioavailability of poorly
733 soluble drugs compared to the pure crystalline state, it is important that the drug can reach high
734 concentrations and that the supersaturation can be maintained. It is generally assumed that the ideal
735 release profile for an ASD system, if not intended for extended or targeted release, is a fast initial drug
736 release from the formulation followed by the maintenance of supersaturation, which can lead to
737 higher absorption and bioavailability. This type of release profile is commonly referred to as the
738 'spring-parachute' effect, with the 'spring' referring to the fast initial drug release and the 'parachute'

739 representing the maintenance of the supersaturation (Shi et al., 2021). If the drug were to crystallize
740 in the dissolution medium, then the benefits of the supersaturation are diminished. The dissolution of
741 drug molecules from an ASD formulation is a complex process, which is influenced by a variety of
742 factors such as the drug and its physicochemical properties, the way the formulation is designed and
743 the polymer that is selected, which also relates to the drug-polymer interactions (Baghel et al., 2016d;
744 Taylor and Zhang, 2016).

745 The initial drug release is highly depending on the polymer that was selected for the formulation and
746 the drug loading of the API in the polymer matrix (Y. Chen et al., 2015b; Indulkar et al., 2019).
747 Depending on the drug-polymer combination, below a certain drug loading, the drug release rate is
748 rapid and polymer-controlled. However, if the drug loading is increased above this critical limit, then
749 the drug release becomes drug-controlled, and the rate and amount of drug release will sharply
750 decrease. The drug loading above which drug release becomes drug-controlled, and the rate and
751 extent of release drop significantly, is generally called 'the limit of congruency' (LoC) (Indulkar et al.,
752 2019; Que et al., 2019; Saboo et al., 2019) . Above the LoC, upon contact with water, the rate of phase
753 separation might be higher than the rate of drug dissolution, resulting in a drug-rich phase with a
754 decreased drug release rate. It has been observed that intermolecular drug-polymer interactions play
755 an important role in the establishment of the LoC. Que, Lou and Zemlyanov et al. have investigated
756 the correlation between the LoC and intermolecular interactions in ASDs of ledipasvir and PVPVA (Que
757 et al., 2019). The researchers found that the relatively low LoC of 5 - 7.5 wt% of the system could be
758 attributed to the fact that drug-polymer interactions were saturated above 10 wt% and drug-drug
759 interactions predominated above the LoC, as was seen in the NMR analysis. This lead to phase
760 separation and surface drug enrichment, hampering the release of the rest of the drug and the
761 polymer, which explained the drop in drug release for drug loadings above 7.5 wt%. (Que et al., 2019).
762 This indicated that intermolecular interactions are in fact important in the establishment of the Loc.
763 Interestingly, the same research group investigated the correlation between the strength of the
764 intermolecular interactions and the LoC, by manufacturing ASDs with PVPVA and APIs with a common
765 chemical scaffold (Que et al., 2021). A negative correlation could be observed between the strength of
766 the intermolecular interactions and the LoC, meaning that APIs which did not interact or did not
767 interact strongly with PVPVA, could reach higher LoC values and showed a higher drug release at larger
768 drug loadings (Que et al., 2021). A follow-up study indicated that the interacting systems displayed a
769 larger amount of polymer in the hydrophobic phase after contact with water, which was suggested to
770 be a determining factor in the increase of the volume of the hydrophobic phase and the formation of
771 an insoluble barrier after phase separation (Deac et al., 2023). However, most of these studies were
772 performed on PVPVA-based systems and studies with other polymers are still limited. Hiew and co-

773 workers compared PVPVA with enteric polymers in lumefantrine-based ASDs and found that the
774 release behavior of the PVPVA-based ASDs was different compared to the enteric polymers (Hiew et
775 al., 2022). The dissolution rate from the ASDs containing enteric polymers was governed by the release
776 rate of the pure polymer and the drug release decreased with increasing drug loading. It was suggested
777 that this was due to ionic interactions, which diminished hydration of the polymer carboxylate ions,
778 limiting dissolution of the polymer (Hiew et al., 2022).

779 As already mentioned, the improved drug release from ASDs can lead to high drug concentrations and
780 a supersaturated solution as a consequence. Generally, the maximum theoretical supersaturation,
781 which can be defined as the highest possible drug concentration where the drug is still present in the
782 aqueous medium as free drug molecules is often termed the 'amorphous solubility' (Murdande et al.,
783 2010). When the drug concentration exceeds the amorphous solubility, liquid-liquid phase separation
784 (LLPS) may occur, without the crystallization of the drug. The occurrence of LLPS entails the equilibrium
785 between a drug-rich phase, existing as colloidal nano-droplets, and a water-rich phase where the
786 concentration of the drug is similar to the amorphous solubility (see *Figure 7*) (Ilevbare and Taylor,
787 2013). The appearance of drug-rich nano-droplets and LLPS often happens in ASDs where a congruent
788 polymer-controlled drug release is observed, as this is correlated with a higher rate and extent of drug
789 release (Que et al., 2021). Drug-rich nano-droplets have been observed to act as a kind of 'reservoir'
790 and could lead to higher drug plasma concentrations compared to ASD systems that lead to similar
791 supersaturation degrees but do not form drug-rich aggregates (Saboo et al., 2019). It has been
792 observed by Qian et al. that the LLPS onset point is also related to the intermolecular interaction
793 between drug and polymer. The researchers found that stronger interactions resulted in a higher LLPS
794 onset concentration and higher maximum achievable free drug. However, this effect depended on the
795 type of interactions that were present between the drug and polymer. Hydrogen bonding appeared to
796 be more sensitive to disruption by water and affected the LLPS onset point to a lesser extent (Qian et
797 al., 2024).

798

799 **Figure 7**

800

801 The behavior of ASDs upon contact with the dissolution medium can be theoretically described using
802 ternary phase diagrams of the API/polymer/water system. A paper by Krummnow et al. provided an
803 excellent depiction of this, describing the pathways an API/polymer system can follow upon contact
804 with water. Water that is absorbed in the ASD can lead to AAPS in the wet ASD, and simultaneously,

805 LLPS of the dissolved drug molecules can occur in the dissolution medium, forming drug-rich
806 nanodroplets. Two ternary phase diagrams, depicting these two situations, can be found in *Figure 8*.

807 **Figure 8**

808 When it comes to the second part of the dissolution process, the maintenance of supersaturation after
809 the initial drug release from the ASD formulation, a couple of factors play a determining role. The
810 physicochemical properties of the drug, such as the crystallization tendency (Van Eerdenbrugh et al.,
811 2010), are important, but again also the polymer that was selected and the composition of the
812 formulation are key factors in the whole process. It has been abundantly reported that the polymer is
813 capable of prolonging and maintaining supersaturation and inhibiting crystallization of the drug in
814 solution (Li et al., 2020). The presence of drug-polymer interactions also appears to be crucial for
815 supersaturation and could limit nucleation and crystal growth of the drug molecules in solution (Y.
816 Chen et al., 2015c; Que et al., 2018). Mendes, Andrzejewski and Pinto et al. investigated the
817 supersaturation of sulfamethoxazole from ASDs which contained either Soluplus or Eudragit EPO and
818 correlated the supersaturation results with the drug-polymer interactions (Mendes et al., 2020). It was
819 observed that higher levels of sulfamethoxazole supersaturation could be attained when it was present
820 in an ASD with Eudragit EPO compared to Soluplus. The increased supersaturation could be attributed
821 to hydrogen bond formation between sulfamethoxazole and Eudragit EPO, which reduced nucleation
822 by increasing the activation energy for the drug to nucleate and decreased crystal growth (Mendes et
823 al., 2020). Ugur, Caggiano and Monson et al. indicated that not only the strength of the drug-polymer
824 interactions play a role in supersaturation but also showed that it is a complex interplay between drug-
825 drug, drug-polymer and polymer-polymer interactions, where the interactions with water and the
826 hydrophobicity of the polymer play a role in the drug release as well (Ugur et al., 2024). Furthermore,
827 it was even shown by Li and Taylor that stronger drug-polymer interactions can lead to a larger
828 solubility suppression when the ASD consisted of a poorly soluble polymer, allowing the tailoring of a
829 more sustained release (Li and Taylor, 2018). A study by Ueda et al. discussed the trade-off that needs
830 to be made considering the impact of intermolecular interactions on the supersaturation of the drug
831 (Ueda et al., 2021). The researchers showed that drug-polymer interactions lead to a reduction of the
832 chemical potential, causing a larger amount of polymer distributing in the drug-rich phase when LLPS
833 occurs. This translates into a couple of advantages such as increased inhibition of crystallization (Ueda
834 et al., 2019) and improvement of the size stability of the drug-rich nano-droplets (Ueda and Taylor,
835 2020). However, increased amounts of polymer in the drug-rich phase also can cause a decrease in the
836 amorphous solubility of the drug, leading to a decline in the amount of free dissolved drug molecules
837 (Ueda et al., 2021).

838 Compared to the influence of drug-polymer intermolecular interactions on the physical stability of
839 ASDs, which is quite straightforward, the effect of interactions on the dissolution process of the ASD is
840 more complex. As discussed above, intermolecular interactions can influence the various stages of
841 dissolution, going from the initial drug release to supersaturation and can affect these processes in
842 both a negative and positive manner depending on the drug-polymer system. When designing an ASD
843 formulation, both the advantages and disadvantages need to be considered and balanced against each
844 other, while also holding the physical stability of the formulation in mind. It is however certain that,
845 despite all the studies that already have been performed, further research is still necessary in order to
846 elucidate the dissolution process in more detail.

847 **6. Conclusion**

848 This review provides a detailed overview of the role that intermolecular interactions play in the
849 formulation and performance of amorphous solid dispersions. First, the thermodynamics and
850 theoretical considerations of interactions in general were discussed in the first part of the review. An
851 overview was given of all characterization techniques that are applied in research to investigate
852 intermolecular interactions in the solid-state and several examples of applications were provided for
853 each technique. The most useful and popular methods to detect interactions are the spectroscopic
854 techniques, especially FT-IR and ssNMR. We consider ssNMR to be one of the most useful and versatile
855 techniques when it comes to probing intermolecular interactions, due to the large variety of pulse
856 sequences and the range of information that can be distilled from the measurements. Combinations
857 with *in silico* simulation methods can be valuable to deepen the understanding of the type of
858 interactions that are formed and the effect on the physical structure.

859 Finally, the role of drug-polymer interactions on the physical stability and drug release of ASDs was
860 explored in more detail. Intermolecular interactions show a definite positive effect on the stability of
861 ASDs, and stronger interactions usually lead to more stable dispersions, and can result in higher drug
862 loadings. The effect of drug-polymer interactions on the drug release is less straightforward. Both
863 positive and negative effects on the drug release have been attributed to intermolecular interactions,
864 and many studies are trying to elucidate how they impact the dissolution process. Nevertheless, more
865 work is still needed to acquire a more extensive comprehension of the process.

866 It is clear that intermolecular interactions play a very important role in various aspects of the
867 formulation and performance of ASDs. However, more systemic studies investigating the interplay and
868 balance between physical stability and dissolution are warranted. A more in-depth understanding of

869 both of these processes needs to be achieved, but especially the combined effect of interactions on

870 both of these aspects should be studied in more detail.

871

872 **Acknowledgements**

873 The authors would like to thank Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO) (grantnumber
874 1SD5524N) for their support.

875

Figure Captions

876

877

878 **Figure 1:** Graphical representation of the Lennard-Jones potential model. Intermolecular potential
879 energy $V_L J$ in function of the distance of a pair of molecules.

880

881 **Figure 2:** Graphical representation of a state diagram for an amorphous solid dispersion with
882 different drug loadings in function of the temperature. The crystalline drug-polymer solubility line,
883 the amorphous drug-polymer solubility line and the glass transition divide the diagram in six distinct
884 regions. **I:** thermodynamically stable glass; **II:** Thermodynamically stable liquid; **III:** supersaturated
885 glass; **IV:** supersaturated liquid; **V:** supersaturated and immiscible glass; **VI:** supersaturated and
886 immiscible liquid. (adapted form Qian et al. 2010 with permission)

887

888 **Figure 3:** FT-IR spectra of NAP, PVPVA, and 10, 20, and 30 wt % NAP and PVPVA in MeOH (A), EtOH
889 (B), PrOH (C), ACN (D), and DCM (E). The following color code was applied: NAP in red, PVPVA in
890 black, 10 wt % NAP in blue, 20 wt % NAP in orange and 30 wt % NAP in green. The transmittance is
891 depicted in arbitrary units. (Reprinted with permission from Dedroog et al. 2022. Copyright 2025
892 American Chemical Society.)

893

894

895 **Figure 4:** ^{15}N CPMAS NMR spectra of crystalline LB freebase, crystalline LB phthalate, amorphous LB
896 freebase, and LB-HPMCP solid dispersions with drug loadings of 40%, 60%, 80%, in the spectral range
897 of -225 to -400 ppm. (Reprinted with permission from Song, Yang, Cheng et al. 2015. Copyright 2025
898 American Chemical Society.)

899

900 **Figure 5:** Possible deviations from the ideal behavior of the glass transition temperature in function
901 of the weight fraction of the drug, as predicted by the Gordon-Taylor equation. (Figure adapted from
902 Baghel et al. 2016 with permission.)

903

904 **Figure 6:** Dielectric loss behavior of NIF (blue ●) and NIF solid dispersions with PVP (black ●),
905 HPMCAS (red ▼), and PAA (green ■) at 60 °C with (a) 10% and (b) 20% w/w polymer concentration.
906 The loss curves have been normalized with respect to the maximum loss value. (Reprinted with
907 permission from Kothari et al. 2015. Copyright 2025 American Chemical Society.)

908

909 **Figure 7:** A visual representation of the dissolution of drug molecules from an ASD where the
910 amorphous solubility is exceeded, and liquid-liquid phase separation occurs. Drug-rich nano droplets
911 are formed and act as a sort of reservoir for the drug molecules in solution.

912

913 **Figure 8:** Schematic ternary phase diagram of an API/polymer/water system with schematic
914 pathways of (a) water sorption and amorphous phase separation (according to (c)) and (b) ASD
915 dissolution in water and liquid–liquid phase separation (according to (d)). The black circle depicts the
916 dry ASD, and the blue dash-dotted line represents the path for (a) water sorption and (b) ASD
917 dissolution. The gray solid line illustrates the miscibility gap (gray area) with gray dash-dotted tie
918 lines. The red triangle denotes the feed point F for (a) amorphous phase separation and for (b)
919 liquid–liquid phase separation. Gray diamonds denote the API-poor phase L1 and the API-rich phase
920 L2. (reprinted from Krummnow et al. 2022 with permission)

921

922

923

924

925

926

927 **References**

- 928 Alonzo, D.E., Raina, S., Zhou, D., Gao, Y., Zhang, G.G.Z., Taylor, L.S., 2012. Characterizing the impact of
929 hydroxypropylmethyl cellulose on the growth and nucleation kinetics of felodipine from
930 supersaturated solutions. *Cryst Growth Des* 12, 1538–1547.
931 https://doi.org/10.1021/CG201590J/ASSET/IMAGES/MEDIUM/CG-2011-01590J_0011.GIF
- 932 Aso, Y., Yoshioka, S., 2006. Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid
933 dispersions as measured by ¹³C-NMR spin-lattice relaxation time. *J Pharm Sci* 95, 318–325.
934 <https://doi.org/10.1002/jps.20545>
- 935 Aulifa, D.L., Al Shofwan, A.A., Megantara, S., Fakhri, T.M., Budiman, A., 2024. Elucidation of Molecular
936 Interactions Between Drug-Polymer in Amorphous Solid Dispersion by a Computational
937 Approach Using Molecular Dynamics Simulations. *Advances and Applications in Bioinformatics
938 and Chemistry* 17, 1–19. <https://doi.org/10.2147/AABC.S441628>
- 939 Baghel, S., Cathcart, H., O'Reilly, N.J., 2016a. Polymeric Amorphous Solid Dispersions: A Review of
940 Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous
941 Solubilization of Biopharmaceutical Classification System Class II Drugs. *J Pharm Sci* 105, 2527–
942 2544. <https://doi.org/10.1016/J.XPHS.2015.10.008>
- 943 Baghel, S., Cathcart, H., O'Reilly, N.J., 2016b. Polymeric Amorphous Solid Dispersions: A Review of
944 Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous
945 Solubilization of Biopharmaceutical Classification System Class II Drugs. *J Pharm Sci* 105, 2527–
946 2544. [https://doi.org/10.1016/J.XPHS.2015.10.008/ASSET/B6F13339-7EB1-4B7E-896C-
947 702C2CB1CCF1/MAIN.ASSETS/GR6.JPG](https://doi.org/10.1016/J.XPHS.2015.10.008/ASSET/B6F13339-7EB1-4B7E-896C-702C2CB1CCF1/MAIN.ASSETS/GR6.JPG)
- 948 Baghel, S., Cathcart, H., O'Reilly, N.J., 2016c. Theoretical and experimental investigation of drug-
949 polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium.
950 *European Journal of Pharmaceutics and Biopharmaceutics* 107, 16–31.
951 <https://doi.org/10.1016/J.EJPB.2016.06.024>
- 952 Baghel, S., Cathcart, H., O'Reilly, N.J., 2016d. Theoretical and experimental investigation of drug-
953 polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium.
954 *European Journal of Pharmaceutics and Biopharmaceutics* 107, 16–31.
955 <https://doi.org/10.1016/J.EJPB.2016.06.024>
- 956 Baird, J.A., Taylor, L.S., 2012a. Evaluation of amorphous solid dispersion properties using thermal
957 analysis techniques. *Adv Drug Deliv Rev* 64, 396–421.
958 <https://doi.org/10.1016/J.ADDR.2011.07.009>
- 959 Baird, J.A., Taylor, L.S., 2012b. Evaluation of amorphous solid dispersion properties using thermal
960 analysis techniques. *Adv Drug Deliv Rev* 64, 396–421.
961 <https://doi.org/10.1016/J.ADDR.2011.07.009>
- 962 Barmpalexis, P., Karagianni, A., Katopodis, K., Vardaka, E., Kachrimanis, K., 2019. Molecular modelling
963 and simulation of fusion-based amorphous drug dispersions in polymer/plasticizer blends.
964 *European Journal of Pharmaceutical Sciences* 130, 260–268.
965 <https://doi.org/10.1016/J.EJPS.2019.02.004>
- 966 Becelaere, J., Van Den Broeck, E., Schoolaert, E., Vanhoorne, V., Van Guyse, J.F.R., Vergaelen, M.,
967 Borgmans, S., Creemers, K., Van Speybroeck, V., Vervaet, C., Hoogenboom, R., De Clerck, K.,

968 2022. Stable amorphous solid dispersion of flubendazole with high loading via electrospinning.
969 Journal of Controlled Release 351, 123–136. <https://doi.org/10.1016/J.JCONREL.2022.09.028>

970 Benet, L.Z., 2013. The role of BCS (biopharmaceutics classification system) and BDDCS
971 (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 102,
972 34–42. <https://doi.org/10.1002/jps.23359>

973 Bhardwaj, S.P., Arora, K.K., Kwong, E., Templeton, A., Clas, S.D., Suryanarayanan, R., 2014.
974 Mechanism of amorphous itraconazole stabilization in polymer solid dispersions: Role of
975 molecular mobility. Mol Pharm 11, 4228–4237.
976 https://doi.org/10.1021/MP5004515/ASSET/IMAGES/MEDIUM/MP-2014-004515_0013.GIF

977 Bhujbal, S. V., Mitra, B., Jain, U., Gong, Y., Agrawal, A., Karki, S., Taylor, L.S., Kumar, S., (Tony) Zhou,
978 Q., 2021a. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.
979 Acta Pharm Sin B 11, 2505–2536. <https://doi.org/10.1016/J.APSB.2021.05.014>

980 Bhujbal, S. V., Mitra, B., Jain, U., Gong, Y., Agrawal, A., Karki, S., Taylor, L.S., Kumar, S., (Tony) Zhou,
981 Q., 2021b. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.
982 Acta Pharm Sin B 11, 2505–2536. <https://doi.org/10.1016/J.APSB.2021.05.014>

983 Billinge, S.J.L., Jensen, K.M.Ø., 2023. Atomic pair distribution function analysis : a primer. Oxford
984 University Press.

985 Bookwala, M., Buckner, I.S., Wildfong, P.L.D., 2022. Implications of Coexistent Halogen and Hydrogen
986 Bonds in Amorphous Solid Dispersions on Drug Solubility, Miscibility, and Mobility. Mol Pharm
987 19, 3959–3972.
988 https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00434/SUPPL_FILE/MP2C00434_SI_001.PDF

989 Bookwala, M., Wildfong, P.L.D., 2023. The Implications of Drug-Polymer Interactions on the Physical
990 Stability of Amorphous Solid Dispersions. Pharmaceutical Research 2023 40:12 40, 2963–2981.
991 <https://doi.org/10.1007/S11095-023-03547-4>

992 Borchardt-Setter, K.A., Yu, J., Stelzer, T., Yu, L., 2024. Surface Enrichment and Depletion of
993 Components in a Ternary Drug-Surfactant-Polymer Amorphous Solid Dispersion. Mol Pharm 21,
994 4074–4081.
995 https://doi.org/10.1021/ACS.MOLPHARMACEUT.4C00444/ASSET/IMAGES/LARGE/MP4C00444_0009.JPEG

997 Budiman, A., Citraloka, Z.G., Muchtaridi, M., Sriwidodo, S., Aulifa, D.L., Rusdin, A., 2022. Inhibition of
998 Crystal Nucleation and Growth in Aqueous Drug Solutions: Impact of Different Polymers on the
999 Supersaturation Profiles of Amorphous Drugs—The Case of Alpha-Mangostin. Pharmaceutics
1000 2022, Vol. 14, Page 2386 14, 2386. <https://doi.org/10.3390/PHARMACEUTICS14112386>

1001 Burnett, D.J., Thielmann, F., Sokoloski, T.D., 2007. Investigating carbamazepine-acetone solvate
1002 formation via Dynamic gravimetric vapor sorption. J Therm Anal Calorim 89, 693–698.
1003 <https://doi.org/10.1007/S10973-006-7957-8/METRICS>

1004 Chan, S.Y., Qi, S., Craig, D.Q.M., 2015. An investigation into the influence of drug–polymer
1005 interactions on the miscibility, processability and structure of polyvinylpyrrolidone-based hot
1006 melt extrusion formulations. Int J Pharm 496, 95–106.
1007 <https://doi.org/10.1016/J.IJPHARM.2015.09.063>

1008 Chen, X., Bates, S., Morris, K.R., 2001. Quantifying amorphous content of lactose using parallel beam
1009 X-ray powder diffraction and whole pattern fitting. *J Pharm Biomed Anal* 26, 63–72.
1010 [https://doi.org/10.1016/S0731-7085\(01\)00346-6](https://doi.org/10.1016/S0731-7085(01)00346-6)

1011 Chen, X., Stoneburner, K., Ladika, M., Kuo, T.C., Kalantar, T.H., 2015. High-Throughput Raman
1012 Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs. *Appl Spectrosc*
1013 69, 1271–1280. <https://doi.org/10.1366/15-07914>

1014 Chen, Y., Liu, C., Chen, Z., Su, C., Hageman, M., Hussain, M., Haskell, R., Stefanski, K., Qian, F., 2015a.
1015 Drug-polymer-water interaction and its implication for the dissolution performance of
1016 amorphous solid dispersions. *Mol Pharm* 12, 576–589. <https://doi.org/10.1021/mp500660m>

1017 Chen, Y., Liu, C., Chen, Z., Su, C., Hageman, M., Hussain, M., Haskell, R., Stefanski, K., Qian, F., 2015b.
1018 Drug-polymer-water interaction and its implication for the dissolution performance of
1019 amorphous solid dispersions. *Mol Pharm* 12, 576–589.
1020 https://doi.org/10.1021/MP500660M/ASSET/IMAGES/MEDIUM/MP-2014-00660M_0009.GIF

1021 Chen, Y., Liu, C., Chen, Z., Su, C., Hageman, M., Hussain, M., Haskell, R., Stefanski, K., Qian, F., 2015c.
1022 Drug-polymer-water interaction and its implication for the dissolution performance of
1023 amorphous solid dispersions. *Mol Pharm* 12, 576–589.
1024 https://doi.org/10.1021/MP500660M/ASSET/IMAGES/MEDIUM/MP-2014-00660M_0009.GIF

1025 Chen, Z., Huang, C., Yao, X., Benmore, C.J., Yu, L., 2021. Structures of glass-forming liquids by x-ray
1026 scattering: Glycerol, xylitol, and D-sorbitol. *J Chem Phys* 155, 244508.
1027 https://doi.org/10.1063/5.0073986/14840258/244508_1_ACCEPTED_MANUSCRIPT.PDF

1028 Chen, Z., Nie, H., Benmore, C.J., Smith, P.A., Du, Y., Byrn, S., Templeton, A.C., Su, Y., 2023. Probing
1029 Molecular Packing of Amorphous Pharmaceutical Solids Using X-ray Atomic Pair Distribution
1030 Function and Solid-State NMR. *Mol Pharm* 20, 5763–5777.
1031 https://doi.org/10.1021/ACS.MOLPHARMACEUT.3C00628/SUPPL_FILE/MP3C00628_SI_001.PDF

1032 Chieng, N., Trnka, H., Boetker, J., Pikal, M., Rantanen, J., Grohgan, H., 2013. Detecting phase
1033 separation of freeze-dried binary amorphous systems using pair-wise distribution function and
1034 multivariate data analysis. *Int J Pharm* 454, 167–173.
1035 <https://doi.org/10.1016/J.IJPHARM.2013.07.030>

1036 Christy, A.A., Ozaki, Y., Gregoriou, V.G., 2001. Modern fourier transform infrared spectroscopy 356.

1037 David, W.I.F., Shankland, K., 2008. Structure determination from powder diffraction data. *Acta*
1038 *Crystallogr A* 64, 52–64. <https://doi.org/10.1107/S0108767307064252>

1039 De Araujo, G.L.B., Benmore, C.J., Byrn, S.R., 2017. Local Structure of Ion Pair Interaction in Lapatinib
1040 Amorphous Dispersions characterized by Synchrotron X-Ray diffraction and Pair Distribution
1041 Function Analysis. *Scientific Reports* 2017 7:1 7, 1–10. <https://doi.org/10.1038/srep46367>

1042 Deac, A., Qi, Q., Indulkar, A.S., Purohit, H.S., Gao, Y., Zhang, G.G.Z., Taylor, L.S., 2023. Dissolution
1043 Mechanisms of Amorphous Solid Dispersions: Role of Drug Load and Molecular Interactions.
1044 *Mol Pharm* 20, 722–737.
1045 https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00892/SUPPL_FILE/MP2C00892_SI_001.PDF

1046 Dedroog, S., Adriaensens, P., Van Den Mooter, G., 2022. Gaining Insight into the Role of the Solvent
1047 during Spray Drying of Amorphous Solid Dispersions by Studying Evaporation Kinetics. *Mol*

1048 Pharm 19, 1604–1618.
1049 https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00095/SUPPL_FILE/MP2C00095_SI_001.PDF

1050 Dedroog, S., Pas, T., Vergauwen, B., Huygens, C., Van den Mooter, G., 2020. Solid-state analysis of
1051 amorphous solid dispersions: Why DSC and XRPD may not be regarded as stand-alone
1052 techniques. *J Pharm Biomed Anal* 178, 112937. <https://doi.org/10.1016/J.JPBA.2019.112937>

1053 Defrese, M.K., Farmer, M.A., Long, Y., Timmerman, L.R., Bae, Y., Marsac, P.J., 2020. Approaches to
1054 Understanding the Solution-State Organization of Spray-Dried Dispersion Feed Solutions and Its
1055 Translation to the Solid State. *Mol Pharm.*
1056 <https://doi.org/10.1021/acs.molpharmaceut.0c00729>

1057 Dohrn, S., Luebbert, C., Lehmkemper, K., Kyeremateng, S.O., Degenhardt, M., Sadowski, G., 2021.
1058 Solvent influence on the phase behavior and glass transition of Amorphous Solid Dispersions.
1059 *European Journal of Pharmaceutics and Biopharmaceutics* 158, 132–142.
1060 <https://doi.org/10.1016/j.ejpb.2020.11.002>

1061 Duer, M.J., 2004. *Introduction to solid-state NMR spectroscopy*. Blackwell.

1062 Fox, T., 1952. Influence of diluent and of copolymer composition on the glass temperature of a
1063 polymer system. *Bull. Am. Phys.*

1064 González Cortes, P., Araya-Hermosilla, R., Wrighton-Araneda, K., Cortés-Arriagada, D., Picchioni, F.,
1065 Yan, F., Rudolf, P., Bose, R.K., Quero, F., 2023. Effect of intermolecular interactions on the glass
1066 transition temperature of chemically modified alternating polyketones. *Mater Today Chem* 34,
1067 101771. <https://doi.org/10.1016/J.MTCHEM.2023.101771>

1068 Gordon; Taylor, J.S., 1952. Ideal co-polymers and the second order transitions of synthetic rubbers.
1069 *Journal of Applied Chemistry* 2, 493–500.

1070 Gross, J., Sadowski, G., 2001. Perturbed-chain SAFT: An equation of state based on a perturbation
1071 theory for chain molecules. *Ind Eng Chem Res* 40, 1244–1260.
1072 <https://doi.org/10.1021/ie0003887>

1073 Hiew, T.N., Zemlyanov, D.Y., Taylor, L.S., 2022. Balancing Solid-State Stability and Dissolution
1074 Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and
1075 Drug-Polymer Interactions. *Mol Pharm* 19, 392–413.
1076 https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00481/ASSET/IMAGES/LARGE/MP1C00481_0013.JPEG
1077

1078 Hu, Z., Xu, P., Ashour, E.A., Repka, M.A., 2022. Prediction and Construction of Drug-Polymer Binary
1079 System Thermodynamic Phase Diagram in Amorphous Solid Dispersions (ASDs). *AAPS*
1080 *PharmSciTech* 23, 1–12. <https://doi.org/10.1208/S12249-022-02319-4/FIGURES/8>

1081 Huang, J., Wigent, R.J., Schwartz, J.B., 2008. Drug–polymer interaction and its significance on the
1082 physical stability of nifedipine amorphous dispersion in microparticles of an ammonio
1083 methacrylate copolymer and ethylcellulose binary blend. *J Pharm Sci* 97, 251–262.
1084 <https://doi.org/10.1002/JPS.21072>

1085 Hunter, N., 2016. Dynamic Vapour Sorption, in: *Principles of Thermal Analysis and Calorimetry*. The
1086 Royal Society of Chemistry, pp. 47–66. <https://doi.org/10.1039/BK9781782620518-00047>

1087 Ilevbare, G.A., Taylor, L.S., 2013. Liquid-liquid phase separation in highly supersaturated aqueous
1088 solutions of poorly water-soluble drugs: Implications for solubility enhancing formulations.

1089 Cryst Growth Des 13, 1497–1509.
1090 https://doi.org/10.1021/CG301679H/ASSET/IMAGES/MEDIUM/CG-2012-01679H_0011.GIF

1091 Indulkar, A.S., Lou, X., Zhang, G.G.Z., Taylor, L.S., 2019. Insights into the Dissolution Mechanism of
1092 Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for
1093 Enhanced Performance. *Mol Pharm* 16, 1327–1339.
1094 https://doi.org/10.1021/ACS.MOLPHARMACEUT.8B01261/ASSET/IMAGES/MEDIUM/MP-2018-01261V_0010.GIF
1095

1096 Janssens, S., Van den Mooter, G., 2009. Review: physical chemistry of solid dispersions. *Journal of*
1097 *Pharmacy and Pharmacology* 61, 1571–1586. <https://doi.org/10.1211/jpp/61.12.0001>

1098 Kabedev, A., Zhuo, X., Leng, D., Foderà, V., Zhao, M., Larsson, P., Bergström, C.A.S., Löbmann, K.,
1099 2022. Stabilizing Mechanisms of β -Lactoglobulin in Amorphous Solid Dispersions of
1100 Indomethacin. *Mol Pharm* 19, 3922–3933.
1101 https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00397/ASSET/IMAGES/LARGE/MP2C00397_0009.JPEG
1102

1103 Kachel, S., Scharfer, P., Schabel, W., 2013. Sorption isotherms of mixtures of polymers, proteins and
1104 electrolytes—Measurement data and model predictions. *Chemical Engineering and Processing: Process Intensification* 68, 45–54. <https://doi.org/10.1016/J.CEP.2012.09.006>

1106 Kapourani, A., Eleftheriadou, K., Kontogiannopoulos, K.N., Barmapalexis, P., 2021. Evaluation of
1107 rivaroxaban amorphous solid dispersions physical stability via molecular mobility studies and
1108 molecular simulations. *European Journal of Pharmaceutical Sciences* 157, 105642.
1109 <https://doi.org/10.1016/J.EJPS.2020.105642>

1110 Karplus, M., McCammon, J.A., 2002. Molecular dynamics simulations of biomolecules. *Nat Struct Biol*
1111 9, 646–652. <https://doi.org/10.1038/NSB0902-646>

1112 Keraticewanun, S., Yoshihashi, Y., Sutanthavibul, N., Terada, K., Chatchawalsaisin, J., 2015. An
1113 investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy. *Pharm Res*
1114 32, 2458–2473. <https://doi.org/10.1007/S11095-015-1638-X>

1115 Kestur, U.S., Taylor, L.S., 2010. Role of polymer chemistry in influencing crystal growth rates from
1116 amorphous felodipine. *CrystEngComm* 12, 2390–2397. <https://doi.org/10.1039/C001905D>

1117 Knopp, M.M., Olesen, N.E., Holm, P., Langguth, P., Holm, R., Rades, T., 2015. Influence of Polymer
1118 Molecular Weight on Drug-Polymer Solubility: A Comparison between Experimentally
1119 Determined Solubility in PVP and Prediction Derived from Solubility in Monomer. *J Pharm Sci*
1120 104, 2905–2912. <https://doi.org/10.1002/jps.24410>

1121 Kothari, K., Ragoonanan, V., Suryanarayanan, R., 2015a. The role of drug-polymer hydrogen bonding
1122 interactions on the molecular mobility and physical stability of nifedipine solid dispersions. *Mol Pharm* 12, 162–170. https://doi.org/10.1021/MP5005146/SUPPL_FILE/MP5005146_SI_001.PDF
1123

1124 Kothari, K., Ragoonanan, V., Suryanarayanan, R., 2015b. The role of drug-polymer hydrogen bonding
1125 interactions on the molecular mobility and physical stability of nifedipine solid dispersions. *Mol Pharm* 12, 162–170. https://doi.org/10.1021/MP5005146/SUPPL_FILE/MP5005146_SI_001.PDF
1126

1127 Krishna Kumar, N.S., Suryanarayanan, R., 2022. Crystallization Propensity of Amorphous
1128 Pharmaceuticals: Kinetics and Thermodynamics. *Mol Pharm* 19, 472–483.
1129 https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00839/SUPPL_FILE/MP1C00839_SI_001.PDF

- 1130 Kruk, D., Privalov, A., Medycki, W., Uniszkiwicz, C., Masierak, W., Jakubas, R., 2012. NMR Studies of
 1131 Solid-State Dynamics. *Annu Rep NMR Spectrosc* 76, 67–138. <https://doi.org/10.1016/B978-0->
 1132 12-397019-0.00003-0
- 1133 Krummnow, A., Danzer, A., Voges, K., Kyeremateng, S.O., Degenhardt, M., Sadowski, G., 2023.
 1134 Kinetics of Water-Induced Amorphous Phase Separation in Amorphous Solid Dispersions via
 1135 Raman Mapping. *Pharmaceutics* 15. <https://doi.org/10.3390/PHARMACEUTICS15051395>
- 1136 Kwei, T.K., 1984. The effect of hydrogen bonding on the glass transition temperatures of polymer
 1137 mixtures. *Journal of polymer science. Polymer letters edition* 22, 307–313.
 1138 <https://doi.org/10.1002/POL.1984.130220603>
- 1139 Lafitte, T., Apostolakou, A., Avendaño, C., Galindo, A., Adjiman, C.S., Müller, E.A., Jackson, G., 2013.
 1140 Accurate statistical associating fluid theory for chain molecules formed from Mie segments.
 1141 *Journal of Chemical Physics* 139, 154504. <https://doi.org/10.1063/1.4819786/193734>
- 1142 Larkin, P.J., 2017. Infrared and Raman Spectroscopy: Principles and Spectral Interpretation. *Infrared
 1143 and Raman Spectroscopy: Principles and Spectral Interpretation* 1–276.
 1144 <https://doi.org/10.1016/C2015-0-00806-1>
- 1145 Levitt, M.H., 2015. Spin Dynamics: Basics of Nuclear Magnetic Resonance. Chapter 1. Matter, Wiley.
 1146 John Wiley & Sons, Ltd.
- 1147 Li, H., Zhang, M., Xiong, L., Feng, W., Williams, R.O., 2020. Bioavailability Improvement of
 1148 Carbamazepine via Oral Administration of Modified-Release Amorphous Solid Dispersions in
 1149 Rats. *Pharmaceutics* 2020, Vol. 12, Page 1023 12, 1023.
 1150 <https://doi.org/10.3390/PHARMACEUTICS12111023>
- 1151 Li, J., Duggirala, N.K., Kumar, N.S.K., Su, Y., Suryanarayanan, R., 2022. Design of Ternary Amorphous
 1152 Solid Dispersions for Enhanced Dissolution of Drug Combinations. *Mol Pharm* 19, 2950–2961.
 1153 https://doi.org/10.1021/ACS.MOLPHARMACEUT.2C00307/SUPPL_FILE/MP2C00307_SI_001.PDF
- 1154 Li, N., Taylor, L.S., 2018. Tailoring supersaturation from amorphous solid dispersions. *Journal of
 1155 Controlled Release* 279, 114–125. <https://doi.org/10.1016/J.JCONREL.2018.04.014>
- 1156 Liu, C., Xu, C.Q., Yu, J., Pui, Y., Chen, H., Wang, S., Zhu, A.D., Li, J., Qian, F., 2019. Impact of a Single
 1157 Hydrogen Substitution by Fluorine on the Molecular Interaction and Miscibility between
 1158 Sorafenib and Polymers. *Mol Pharm* 16, 318–326.
 1159 [https://doi.org/10.1021/ACS.MOLPHARMACEUT.8B00970/ASSET/IMAGES/LARGE/MP-2018-
 1160 00970A_0006.JPEG](https://doi.org/10.1021/ACS.MOLPHARMACEUT.8B00970/ASSET/IMAGES/LARGE/MP-2018-00970A_0006.JPEG)
- 1161 Lu, J., Cuellar, K., Hammer, N.I., Jo, S., Gryczke, A., Kolter, K., Langley, N., Repka, M.A., 2016. Solid-
 1162 state Characterization of Felodipine-Soluplus® Amorphous Solid Dispersions. *Drug Dev Ind
 1163 Pharm* 42, 485. <https://doi.org/10.3109/03639045.2015.1104347>
- 1164 Lu, X., Huang, C., Lowinger, M.B., Yang, F., Xu, W., Brown, C.D., Hesk, D., Koynov, A., Schenck, L., Su,
 1165 Y., 2019. Molecular Interactions in Posaconazole Amorphous Solid Dispersions from Two-
 1166 Dimensional Solid-State NMR Spectroscopy. *Mol Pharm* 16, 2579–2589.
 1167 <https://doi.org/10.1021/acs.molpharmaceut.9b00174>
- 1168 Luebbert, C., Klanke, C., Sadowski, G., 2018. Investigating phase separation in amorphous solid
 1169 dispersions via Raman mapping. *Int J Pharm* 535, 245–252.
 1170 <https://doi.org/10.1016/J.IJPHARM.2017.11.014>

1171 Ma, S.M., Zhao, L., Wang, Y.L., Zhu, Y.L., Lu, Z.Y., 2020. The coarse-grained models of poly(ethylene
1172 oxide) and poly(propylene oxide) homopolymers and poloxamers in big multipole water (BMW)
1173 and MARTINI frameworks. *Physical Chemistry Chemical Physics* 22, 15976–15985.
1174 <https://doi.org/10.1039/D0CP01006E>

1175 Malick, N.S.H.S.D.S.C.; H.C.A.W., 2014. *Amorphous Solid Dispersion*.

1176 Maniruzzaman, M., Snowden, M.J., Bradely, M.S., Douroumis, D., 2015. Studies of intermolecular
1177 interactions in solid dispersions using advanced surface chemical analysis. *RSC Adv* 5, 74212–
1178 74219. <https://doi.org/10.1039/C5RA13176F>

1179 Marsac, P.J., Shamblin, S.L., Taylor, L.S., 2006a. Theoretical and practical approaches for prediction of
1180 drug-polymer miscibility and solubility. *Pharm Res* 23, 2417–2426.
1181 <https://doi.org/10.1007/S11095-006-9063-9>

1182 Marsac, P.J., Shamblin, S.L., Taylor, L.S., 2006b. Theoretical and practical approaches for prediction of
1183 drug-polymer miscibility and solubility. *Pharm Res* 23, 2417–2426.
1184 <https://doi.org/10.1007/S11095-006-9063-9/TABLES/2>

1185 Mazurek, A.H., Szeleszczuk, Ł., Pisklak, D.M., 2020. Periodic DFT Calculations—Review of Applications
1186 in the Pharmaceutical Sciences. *Pharmaceutics* 2020, Vol. 12, Page 415 12, 415.
1187 <https://doi.org/10.3390/PHARMACEUTICS12050415>

1188 Mehring, M., 1996. K. Schmidt-Rohr and H. W. Spiess: “Multidimensional Solid-State NMR and
1189 Polymers”, Academic Press, London 1994, ISBN 0-12-626630-1, S. 478, Preis: 65 £. *Berichte der*
1190 *Bunsengesellschaft für physikalische Chemie* 100, 1091–1091.
1191 <https://doi.org/10.1002/BBPC.19961000669>

1192 Mendes, C., Andrzejewski, R.G., Pinto, J.M.O., de Novais, L.M.R., Barison, A., Silva, M.A.S., Parize, A.L.,
1193 2020. Impact of Drug-Polymer Interaction in Amorphous Solid Dispersion Aiming for the
1194 Supersaturation of Poorly Soluble Drug in Biorelevant Medium. *AAPS PharmSciTech* 21, 1–10.
1195 <https://doi.org/10.1208/S12249-020-01737-6/FIGURES/7>

1196 Meng, F., Dave, V., Chauhan, H., 2015. Qualitative and quantitative methods to determine miscibility
1197 in amorphous drug–polymer systems. *European Journal of Pharmaceutical Sciences* 77, 106–
1198 111. <https://doi.org/10.1016/J.EJPS.2015.05.018>

1199 Mesallati, H., Umerska, A., Paluch, K.J., Tajber, L., 2017. Amorphous Polymeric Drug Salts as Ionic
1200 Solid Dispersion Forms of Ciprofloxacin. *Mol Pharm* 14, 2209–2223.
1201 https://doi.org/10.1021/ACS.MOLPHARMACEUT.7B00039/SUPPL_FILE/MP7B00039_SI_001.PDF

1202 Mistry, P., Mohapatra, S., Gopinath, T., Vogt, F.G., Suryanarayanan, R., 2015. Role of the Strength of
1203 Drug-Polymer Interactions on the Molecular Mobility and Crystallization Inhibition in
1204 Ketoconazole Solid Dispersions. *Mol Pharm* 12, 3339–3350.
1205 <https://doi.org/10.1021/acs.molpharmaceut.5b00333>

1206 Murdande, S.B., Pikal, M.J., Shanker, R.M., Bogner, R.H., 2010. Solubility advantage of amorphous
1207 pharmaceuticals: I. a thermodynamic analysis. *J Pharm Sci* 99, 1254–1264.
1208 <https://doi.org/10.1002/jps.21903>

1209 Nambiar, A.G., Singh, M., Mali, A.R., Serrano, D.R., Kumar, R., Healy, A.M., Agrawal, A.K., Kumar, D.,
1210 2022. Continuous Manufacturing and Molecular Modeling of Pharmaceutical Amorphous Solid

- 1211 Dispersions. *AAPS PharmSciTech* 2022 23:7 23, 1–26. [https://doi.org/10.1208/S12249-022-](https://doi.org/10.1208/S12249-022-02408-4)
1212 02408-4
- 1213 Netchacovitch, L., Dumont, E., Cailletaud, J., Thiry, J., De Bleye, C., Sacré, P.Y., Boiret, M., Evrard, B.,
1214 Hubert, P., Ziemons, E., 2017. Development of an analytical method for crystalline content
1215 determination in amorphous solid dispersions produced by hot-melt extrusion using
1216 transmission Raman spectroscopy: A feasibility study. *Int J Pharm* 530, 249–255.
1217 <https://doi.org/10.1016/J.IJPHARM.2017.07.052>
- 1218 Newman, A., Knipp, G., Zografi, G., 2012. Assessing the performance of amorphous solid dispersions.
1219 *J Pharm Sci* 101, 1355–1377. <https://doi.org/10.1002/jps.23031>
- 1220 Okada, H., Ueda, K., Yasuda, Y., Higashi, K., Inoue, M., Ito, M., Noguchi, S., Kawakami, K., Moribe, K.,
1221 2020. Correlation between drug dissolution and resistance to water-induced phase separation
1222 in solid dispersion formulations revealed by solid-state NMR spectroscopy. *Int J Pharm* 577.
1223 <https://doi.org/10.1016/J.IJPHARM.2020.119086>
- 1224 Palermo, R.N., Anderson, C.A., Drennen, J.K., 2012. Review: Use of thermal, diffraction, and
1225 vibrational analytical methods to determine mechanisms of solid dispersion stability. *J Pharm*
1226 *Innov* 7, 2–12. <https://doi.org/10.1007/S12247-012-9121-2/TABLES/1>
- 1227 Paudel, A., Geppi, M., Van Den Mooter, G., 2014. Structural and dynamic properties of amorphous
1228 solid dispersions: The role of solid-state nuclear magnetic resonance spectroscopy and
1229 relaxometry. *J Pharm Sci* 103, 2635–2662. <https://doi.org/10.1002/jps.23966>
- 1230 Pinder, J.W., Major, G.H., Baer, D.R., Terry, J., Whitten, J.E., Čechal, J., Crossman, J.D., Lizarbe, A.J.,
1231 Jafari, S., Easton, C.D., Baltrusaitis, J., van Spronsen, M.A., Linford, M.R., 2024. Avoiding
1232 common errors in X-ray photoelectron spectroscopy data collection and analysis, and properly
1233 reporting instrument parameters. *Applied Surface Science Advances* 19, 100534.
1234 <https://doi.org/10.1016/J.APSADV.2023.100534>
- 1235 Pugliese, A., Toresco, M., Mcnamara, D., Iuga, D., Abraham, A., Tobyn, M., Hawarden, L.E., Blanc, F.,
1236 2021. Drug-Polymer Interactions in Acetaminophen/Hydroxypropylmethylcellulose Acetyl
1237 Succinate Amorphous Solid Dispersions Revealed by Multidimensional Multinuclear Solid-State
1238 NMR Spectroscopy. *Mol Pharm* 18, 3519–3531.
1239 https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00427/SUPPL_FILE/MP1C00427_SI_001.PDF
- 1240 Punčochová, K., Heng, J.Y.Y., Beránek, J., Štěpánek, F., 2014. Investigation of drug–polymer
1241 interaction in solid dispersions by vapour sorption methods. *Int J Pharm* 469, 159–167.
1242 <https://doi.org/10.1016/J.IJPHARM.2014.04.048>
- 1243 Punčochová, K., Vukosavljevic, B., Hanuš, J., Beránek, J., Windbergs, M., Štěpánek, F., 2016. Non-
1244 invasive insight into the release mechanisms of a poorly soluble drug from amorphous solid
1245 dispersions by confocal Raman microscopy. *European Journal of Pharmaceutics and*
1246 *Biopharmaceutics* 101, 119–125. <https://doi.org/10.1016/J.EJPB.2016.02.001>
- 1247 Qian, F., Huang, J., Hussain, M.A., 2010. Drug–Polymer Solubility and Miscibility: Stability
1248 Consideration and Practical Challenges in Amorphous Solid Dispersion Development. *J Pharm*
1249 *Sci* 99, 2941–2947. <https://doi.org/10.1002/jps.22074>
- 1250 Qian, K., Stella, L., Liu, F., Jones, D.S., Andrews, G.P., Tian, Y., 2024. Kinetic and Thermodynamic
1251 Interplay of Polymer-Mediated Liquid-Liquid Phase Separation for Poorly Water-Soluble Drugs.
1252 *Mol Pharm* 21, 2878–2893.

1253 https://doi.org/10.1021/ACS.MOLPHARMACEUT.4C00033/ASSET/IMAGES/LARGE/MP4C00033_
1254 0013.JPEG

1255 Que, C., Deac, A., Zemlyanov, D.Y., Qi, Q.Q., Indulkar, A.S., Gao, Y., Zhang, G.G.Z., Taylor, L.S., 2021.
1256 Impact of Drug-Polymer Intermolecular Interactions on Dissolution Performance of
1257 Copovidone-Based Amorphous Solid Dispersions. *Mol Pharm* 18, 3496–3508.
1258 https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00419/ASSET/IMAGES/LARGE/MP1C00419_
1259 0007.JPEG

1260 Que, C., Gao, Y., Raina, S.A., Zhang, G.G.Z., Taylor, L.S., 2018. Paclitaxel Crystal Seeds with Different
1261 Intrinsic Properties and Their Impact on Dissolution of Paclitaxel-HPMCAS Amorphous Solid
1262 Dispersions. *Cryst Growth Des* 18, 1548–1559.
1263 https://doi.org/10.1021/ACS.CGD.7B01521/SUPPL_FILE/CG7B01521_SI_002.PDF

1264 Que, C., Lou, X., Zemlyanov, D.Y., Mo, H., Indulkar, A.S., Gao, Y., Zhang, G.G.Z., Taylor, L.S., 2019.
1265 Insights into the Dissolution Behavior of Ledipasvir-Copovidone Amorphous Solid Dispersions:
1266 Role of Drug Loading and Intermolecular Interactions. *Mol Pharm* 16, 5054–5067.
1267 https://doi.org/10.1021/ACS.MOLPHARMACEUT.9B01025/ASSET/IMAGES/LARGE/MP9B01025_
1268 0016.JPEG

1269 Rams-Baron, M., Jachowicz, R., Boldyreva, E., Zhou, D., Jamroz, W., Paluch, M., 2018. Amorphous
1270 drugs: Benefits and challenges, *Amorphous Drugs: Benefits and Challenges*. Springer
1271 International Publishing. <https://doi.org/10.1007/978-3-319-72002-9/COVER>

1272 Rawlinson, C.F., Williams, A.C., Timmins, P., Grimsey, I., 2007. Polymer-mediated disruption of drug
1273 crystallinity. *Int J Pharm* 336, 42–48. <https://doi.org/10.1016/J.IJPHARM.2006.11.029>

1274 Ricarte, R.G., Van Zee, N.J., Li, Z., Johnson, L.M., Lodge, T.P., Hillmyer, M.A., 2019. Recent Advances in
1275 Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions. *Mol*
1276 *Pharm* 16, 4089–4103.
1277 https://doi.org/10.1021/ACS.MOLPHARMACEUT.9B00601/ASSET/IMAGES/LARGE/MP9B00601_
1278 0009.JPEG

1279 Rosiak, N., Tykarska, E., Cielecka-Piontek, J., 2024. Myricetin Amorphous Solid Dispersions—
1280 Antineurodegenerative Potential. *Molecules* 29, 1287.
1281 <https://doi.org/10.3390/MOLECULES29061287/S1>

1282 Rumondor, A.C.F., Stanford, L.A., Taylor, L.S., 2009. Effects of polymer type and storage relative
1283 humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. *Pharm*
1284 *Res* 26, 2599–2606. <https://doi.org/10.1007/S11095-009-9974-3/FIGURES/8>

1285 Saboo, S., Mugheirbi, N.A., Zemlyanov, D.Y., Kestur, U.S., Taylor, L.S., 2019. Congruent release of drug
1286 and polymer: A “sweet spot” in the dissolution of amorphous solid dispersions. *Journal of*
1287 *Controlled Release* 298, 68–82. <https://doi.org/10.1016/J.JCONREL.2019.01.039>

1288 Sarpal, K., Delaney, S., Zhang, G.G.Z., Munson, E.J., 2019. Phase Behavior of Amorphous Solid
1289 Dispersions of Felodipine: Homogeneity and Drug-Polymer Interactions. *Mol Pharm* 16, 4836–
1290 4851.
1291 https://doi.org/10.1021/ACS.MOLPHARMACEUT.9B00731/SUPPL_FILE/MP9B00731_SI_001.PDF

1292 Shi, Q., Li, F., Yeh, S., Moinuddin, S.M., Xin, J., Xu, J., Chen, H., Ling, B., 2021. Recent Advances in
1293 Enhancement of Dissolution and Supersaturation of Poorly Water-Soluble Drug in Amorphous

1294 Pharmaceutical Solids: A Review. *AAPS PharmSciTech* 2021 23:1 23, 1–19.
1295 <https://doi.org/10.1208/S12249-021-02137-0>

1296 Song, Y., Yang, X., Chen, X., Nie, H., Byrn, S., Lubach, J.W., 2015. Investigation of Drug–Excipient
1297 Interactions in Lapatinib Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy. *Mol*
1298 *Pharm* 12, 857–866. <https://doi.org/10.1021/MP500692A>

1299 Stephan, S., Staubach, J., Hasse, H., 2020. Review and comparison of equations of state for the
1300 Lennard-Jones fluid. *Fluid Phase Equilib* 523, 112772.
1301 <https://doi.org/10.1016/J.FLUID.2020.112772>

1302 Stockmayer, W.H., 1941. Second Virial Coefficients of Polar Gases. *J Chem Phys* 9, 398–402.
1303 <https://doi.org/10.1063/1.1750922>

1304 Swindells, N., Sykes, C., 1938. The classical equation of state of gaseous helium, neon and argon. *Proc*
1305 *R Soc Lond A Math Phys Sci* 168, 264–283. <https://doi.org/10.1098/RSPA.1938.0173>

1306 Tao, J., Sun, Y., Zhang, G.G.Z., Yu, L., 2009. Solubility of small-molecule crystals in polymers: D-
1307 Mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. *Pharm Res* 26, 855–864.
1308 <https://doi.org/10.1007/S11095-008-9784-Z/FIGURES/12>

1309 Taylor, L.S., Zhang, G.G.Z., 2016. Physical chemistry of supersaturated solutions and implications for
1310 oral absorption. *Adv Drug Deliv Rev* 101, 122–142. <https://doi.org/10.1016/J.ADDR.2016.03.006>

1311 Terban, M.W., Billinge, S.J.L., 2022. Structural Analysis of Molecular Materials Using the Pair
1312 Distribution Function. *Chem Rev* 122, 1208–1272.
1313 https://doi.org/10.1021/ACS.CHEMREV.1C00237/ASSET/IMAGES/LARGE/CR1C00237_0032.JPEG
1314 G

1315 Terban, M.W., Johnson, M., Di Michiel, M., Billinge, S.J.L., 2015. Detection and characterization of
1316 nanoparticles in suspension at low concentrations using the X-ray total scattering pair
1317 distribution function technique. *Nanoscale* 7, 5480–5487. <https://doi.org/10.1039/C4NR06486K>

1318 Trasi, N.S., Bhujbal, S. V., Zemlyanov, D.Y., Zhou, Q. (Tony), Taylor, L.S., 2020. Physical stability and
1319 release properties of lumefantrine amorphous solid dispersion granules prepared by a simple
1320 solvent evaporation approach. *Int J Pharm X* 2, 100052.
1321 <https://doi.org/10.1016/J.IJPX.2020.100052>

1322 Ueda, K., Moseson, D.E., Pathak, V., Taylor, L.S., 2021. Effect of Polymer Species on Maximum
1323 Aqueous Phase Supersaturation Revealed by Quantitative Nuclear Magnetic Resonance
1324 Spectroscopy. *Mol Pharm* 18, 1344–1355.
1325 https://doi.org/10.1021/ACS.MOLPHARMACEUT.0C01174/ASSET/IMAGES/LARGE/MP0C01174_0011.JPEG
1326 0011.JPEG

1327 Ueda, K., Taylor, L.S., 2020. Polymer Type Impacts Amorphous Solubility and Drug-Rich Phase
1328 Colloidal Stability: A Mechanistic Study Using Nuclear Magnetic Resonance Spectroscopy. *Mol*
1329 *Pharm* 17, 1352–1362.
1330 https://doi.org/10.1021/ACS.MOLPHARMACEUT.0C00061/ASSET/IMAGES/MEDIUM/MP0C00061_M001.GIF
1331 1_M001.GIF

1332 Ueda, K., Yamamoto, N., Higashi, K., Moribe, K., 2019. Molecular Mobility Suppression of Ibuprofen-
1333 Rich Amorphous Nanodroplets by HPMC Revealed by NMR Relaxometry and Its Significance
1334 with Respect to Crystallization Inhibition. *Mol Pharm* 16, 4968–4977.

- 1335 https://doi.org/10.1021/ACS.MOLPHARMACEUT.9B00840/ASSET/IMAGES/LARGE/MP9B00840_
1336 [0010.JPEG](https://doi.org/10.1021/ACS.MOLPHARMACEUT.9B00840/ASSET/IMAGES/LARGE/MP9B00840_0010.JPEG)
- 1337 Ugur, B.E., Caggiano, N.J., Monson, S., Bechtold, A.G., Seo, Y., Prud'homme, R.K., Priestley, R.D.,
1338 Webb, M.A., 2024. Molecular Interactions Underlying Dissolution Trends in Cannabidiol-
1339 Polymer Amorphous Solid Dispersions. *Macromolecules* 57, 8287–8297.
1340 <https://doi.org/10.1021/acs.macromol.4c01579>
- 1341 Vaka, S.R.K., Bommana, M.M., Desai, D., Djordjevic, J., Phuapradit, W., Shah, N., 2014. Excipients for
1342 Amorphous Solid Dispersions, in: Shah, N., Sandhu, H., Choi, D.S., Chokshi, H., Malick, A.W.
1343 (Eds.), *Amorphous Solid Dispersions: Theory and Practice*. Springer New York, New York, NY, pp.
1344 123–161. https://doi.org/10.1007/978-1-4939-1598-9_4
- 1345 Van Den Mooter, G., 2012. The use of amorphous solid dispersions: A formulation strategy to
1346 overcome poor solubility and dissolution rate. *Drug Discov Today Technol* 9, e79–e85.
1347 <https://doi.org/10.1016/J.DDTEC.2011.10.002>
- 1348 van der Heide, P., 2011. Introduction, in: *X-Ray Photoelectron Spectroscopy*. John Wiley & Sons, Ltd,
1349 pp. 1–12. <https://doi.org/10.1002/9781118162897.CH1>
- 1350 Van Eerdenbrugh, B., Baird, J.A., Taylor, L.S., 2010. Crystallization Tendency of Active Pharmaceutical
1351 Ingredients Following Rapid Solvent Evaporation—Classification and Comparison with
1352 Crystallization Tendency from Under cooled Melts. *J Pharm Sci* 99, 3826–3838.
1353 <https://doi.org/10.1002/jps.22214>
- 1354 Vankeirsbilck, T., Vercauteren, A., Baeyens, W., Van der Weken, G., Verpoort, F., Vergote, G., Remon,
1355 J.P., 2002. Applications of Raman spectroscopy in pharmaceutical analysis. *TrAC Trends in*
1356 *Analytical Chemistry* 21, 869–877. [https://doi.org/10.1016/S0165-9936\(02\)01208-6](https://doi.org/10.1016/S0165-9936(02)01208-6)
- 1357 Vogt, F.G., Brum, J., Katrincic, L.M., Flach, A., Socha, J.M., Goodman, R.M., Haltiwanger, R.C., 2006.
1358 Physical, crystallographic, and spectroscopic characterization of a crystalline pharmaceutical
1359 hydrate: Understanding the role of water. *Cryst Growth Des* 6, 2333–2354.
1360 <https://doi.org/10.1021/CG060324K>
- 1361 Vogt, F.G., Clawson, J.S., Strohmeier, M., Pham, T.N., Watson, S.A., Edwards, A.J., 2011. New
1362 Approaches to the Characterization of Drug Candidates by Solid-State NMR. *Pharmaceutical*
1363 *Sciences Encyclopedia* 1–77. <https://doi.org/10.1002/9780470571224.PSE418>
- 1364 Wang, B., Wang, D., Zhao, S., Huang, X., Zhang, J., Lv, Y., Liu, X., Lv, G., Ma, X., 2017. Evaluate the
1365 ability of PVP to inhibit crystallization of amorphous solid dispersions by density functional
1366 theory and experimental verify. *European Journal of Pharmaceutical Sciences* 96, 45–52.
1367 <https://doi.org/10.1016/J.EJPS.2016.08.046>
- 1368 Wang, J., Cheung, M.K., Mi, Y., 2002. Miscibility and morphology in crystalline/amorphous blends of
1369 poly (caprolactone)/poly(4-vinylphenol) as studied by DSC, FTIR, and ¹³C solid state NMR.
1370 *Polymer (Guildf)* 43, 1357–1364. [https://doi.org/10.1016/S0032-3861\(01\)00673-5](https://doi.org/10.1016/S0032-3861(01)00673-5)
- 1371 Wang, J., Cheung, M.K., Mi, Y., 2001. Miscibility in blends of poly (4-vinylpyridine)/poly (4-
1372 vinylphenol) as studied by ¹³C solid-state NMR. *Polymer (Guildf)* 42, 3087–3093.
1373 [https://doi.org/10.1016/S0032-3861\(00\)00643-1](https://doi.org/10.1016/S0032-3861(00)00643-1)

1374 Wang, X., Ramírez-Hinestrosa, S., Dobnikar, J., Frenkel, D., 2020. The Lennard-Jones potential: When
1375 (not) to use it. *Physical Chemistry Chemical Physics* 22, 10624–10633.
1376 <https://doi.org/10.1039/C9CP05445F>

1377 Wu, J., Mooter, G. Van den, 2023. The influence of hydrogen bonding between different
1378 crystallization tendency drugs and PVPVA on the stability of amorphous solid dispersions. *Int J*
1379 *Pharm* 646, 123440. <https://doi.org/10.1016/J.IJPHARM.2023.123440>

1380 Xiang, T.-X., Anderson, B.D., 2019. Effects of Molecular Interactions on Miscibility and Mobility of
1381 Ibuprofen in Amorphous Solid Dispersions With Various Polymers. *J Pharm Sci* 108, 178–186.
1382 <https://doi.org/10.1016/j.xphs.2018.10.052>

1383 Yao, X., Huang, C., Benson, E.G., Shi, C., Zhang, G.G.Z., Yu, L., 2020. Effect of Polymers on
1384 Crystallization in Glass-Forming Molecular Liquids: Equal Suppression of Nucleation and Growth
1385 and Master Curve for Prediction. *Cryst Growth Des* 20, 237–244.
1386 https://doi.org/10.1021/ACS.CGD.9B01095/ASSET/IMAGES/LARGE/CG9B01095_0011.JPEG

1387 Yoshioka, M., Hancock, B.C., Zografi, G., 1994. Crystallization of Indomethacin from the Amorphous
1388 State below and above Its Glass Transition Temperature. *J Pharm Sci* 83, 1700–1705.
1389 <https://doi.org/10.1002/JPS.2600831211>

1390 Yuan, X., Sperger, D., Munson, E.J., 2014. Investigating miscibility and molecular mobility of
1391 nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. *Mol Pharm* 11,
1392 329–337. <https://doi.org/10.1021/mp400498n>

1393 Zhang, F., Mao, J., Tian, G., Jiang, H., Jin, Q., 2022. Preparation and Characterization of Furosemide
1394 Solid Dispersion with Enhanced Solubility and Bioavailability. *AAPS PharmSciTech* 23, 1–11.
1395 <https://doi.org/10.1208/S12249-022-02208-W/TABLES/3>

1396 Zhang, J., Liu, Z., Wu, H., Cai, T., 2021. Effect of polymeric excipients on nucleation and crystal growth
1397 kinetics of amorphous fluconazole. *Biomater Sci* 9, 4308–4316.
1398 <https://doi.org/10.1039/D1BM00104C>

1399 Zhang, S., Zhang, X., Meng, J., Lu, L., Du, S., Xu, H., Wu, S., 2022. Study on the Effect of Polymer
1400 Excipients on the Dispersibility, Interaction, Solubility, and Scavenging Reactive Oxygen Species
1401 of Myricetin Solid Dispersion: Experiment and Molecular Simulation. *ACS Omega* 7, 1514–1526.
1402 https://doi.org/10.1021/ACSOMEGA.1C06329/ASSET/IMAGES/LARGE/AO1C06329_0017.JPEG

1403